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1  General 
 
Technion Data 
All reactions were carried out in dry glassware under positive pressure of argon.  THF and Et2O were used following purification from a zeolite drying apparatus (Pure-Solv® Purification System; Innovative Technology©).  All Grignard reagents (incl. MeMgBr solution in Et2O purchased from Sigma–Aldrich; others prepared in-house) were titrated with tert-butanol solution in toluene with 1,10-phenanthroline as indicator.  All other chemicals were used as supplied.  Chromatographic separations were performed on Bio-Lab silica gel 60Å (40–63 μm).  Thin–layer chromatography was performed on Merck© TLC Silica gel 60 F254 and visualised by UV (254 nm), KMnO4 and/or phosphomolybdic acid: 1H and 13C NMR spectra were recorded on Bruker© Avance 500, 400, and 300 spectrometers.  Residual solvent peaks were used as internal standards.[1] Chemical shifts are quoted in ppm using the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; qn quintet; sx sextet; non nonet, m multiplet; br, broad; or a combination thereof.  The coupling constants J are measured in Hz. Mass spectra (APCI or ESI) were recorded at the Schulich Faculty of Chemistry, Technion–Israel Institute of Technology. 
Caltech Data 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) in flame-dried glassware under a nitrogen atmosphere using dry, deoxygentated solvents (distilled or passed over a column of activated alumina).[2]  Commercially available reagents were used as received.  Reactions requiring external heat were modulated to the specified temperatures using an IKAmag temperature controller.  Thin-layer chromatography (TLC) was performed using E. Merck silica gel 60 F254 pre-coated plates (250 nm) and visualized by UV fluorescence quenching, potassium permanganate, or p-anisaldehyde staining.  Silicycle SiliaFlash P60 Academic Silica gel (particle size 40–63 μm) was used for flash chromatography.  (S)-t-BuPHOX,[3]  (S)-(CF3)-t-BuPHOX,[4] and bis(dibenzylideneacetone) palladium(0) (Pd(dba)2) were prepared by known methods.  Commercially available C-2 symmetric ligands ((R,R)-DACH-naphthyl Trost ligand, (R,R)-DACH-phenyl Trost ligand, (R,R)-ANDEN-Phenyl Trost Ligand) were purchased from Sigma Aldrich, used as received, and stored in a glovebox.  Grubbs’s Generation II catalyst was purchased from Materia Inc. and used as received.  1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 MHz and 126 MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and 77.16, respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in frequency of absorption (cm-1).  Analytical chiral SFC was performed with a Mettler SFC supercritical CO2 analytical chromatography system with Chiralpak AD-H column, OD-H column, and OJ-H column obtained from Daicel Chemical Industries, Ltd. High resolution mass spectra (HRMS) were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H High Resolution Mass Spectrometer in fast atom bombardment (FAB+) or electron ionization (EI+) mode, or from the Caltech Center for Catalysis and Chemical Synthesis using an Agilent 6200 series TOF with an Agilent G1978A Multimode source in mixed (Multimode ESI/APCI) ionization mode.  Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm.  
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2  Supplementary Tables 
 
Table 1. Evaluation of PHOX-ligands. 
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Table 2.  Evaluation of C2-symmetric ligands. 
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3  Procedures 
3.1  Ynecarbamates 
 
Representative Procedure A [Hsung coupling with cyclic carbamates][5] 
A slurry of ynecarbamate (1.0 equiv), 1-bromoalkyne (1.2 equiv), CuSO4∙5H2O (0.2 equiv) 1,10-phenanthroline monohydrate (0.4 equiv), and K2CO3 (2.0 equiv) in toluene (50–60 mL) was stirred at 70–90 °C for 24 h.  The mixture was cooled to room temperature, diluted with DCM and filtered through silica, washed with DCM, concentrated under reduced pressure and the crude residue was purified by flash chromatography with EtOAc/Hex (1:5) to give the product. 
 
3-(Hex-1-yn-1-yl)oxazolidin-2-one (1a)[5] 
Representative Procedure A.   Prepared from oxazolidin-2-one (2.4150 g, 27.7 mmol, 1.0 equiv) and 1-bromohex-1-yne (5.362 g, 33.3 mmol, 1.2 equiv) using K2CO3 (7.66 g. 55.5 mmol, 2.0 equiv), CuSO4·5H2O (1.383 g, 5.55 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.220 g, 11.1 mmol, 0.4 equiv) and toluene (55 mL) at 70 °C to give the desired product as a pale yellow oil (4.417 g, 26.4 mmol, 95%): 1H NMR (CDCl3, 400 MHz) δ 4.39 (t, 2H, J = 7.9), 3.85 (t, 2H, J = 7.9), 2.28 (t. 2H, J = 6.9), 1.49 (qn, 2H, J = 6.9), 1.38 (sx, 2H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 156.8, 71.2, 70.1, 62.9, 47.1, 30.9, 22.0, 18.1, 13.6. HRMS (ESI) for C9H14NO2 [M+H]+ found 168.1011, calc. 168.1019. 
 
  
S7  
 
 
3-(Oct-1-yn-1-yl)oxazolidin-2-one (1p)[7] 
Representative Procedure A.  Prepared from oxazolidin-2-one (3.1075 g, 35.7 mmol, 1.0 equiv) and 1-bromooct-1-yne (8.097 g, 42.8 mmol, 1.2 equiv) using K2CO3 (9.858 g. 71.4 mmol, 2.0 equiv), CuSO4·5H2O (1.782 g, 7.1 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.829 g, 14.3 mmol, 0.4 equiv) and toluene (60 mL) at 90 °C to give the desired product as a pale yellow oil (6.178 g, 31.6 mmol, 89%): 1H NMR (CDCl3, 400 MHz) δ 4.40 (t, 2H. J = 8.2), 3.87 (t, 2H, J = 8.2), 2.29 (t, 2H, J = 7.0), 1.52 (qn, 2H, J =7.0), 1.40–1.20 (6H), 0.89 (t, 2H, J =7.0); 
13C NMR (CDCl3, 100 MHz) δ 156.8, 71.4, 70.1, 62.9, 47.2, 31.5, 28.9, 28.7, 22.7, 18.5, 14.2. HRMS (ESI) for C11H18NO2 [M+H]+ found 196.1343, calc. 196.1332. 
 
Representative Procedure B [Hsung coupling with acyclic carbamates]:[Error! Bookmark not defined.] A slurry of ynecarbamate (1.0 equiv), 1-bromoalkyne (1.2 equiv), CuSO4∙5H2O (0.2 equiv) 1,10-phenanthroline monohydrate (0.4 equiv), and K3PO4·H2O (2.0 equiv) in toluene (50–60 mL) was stirred at 70–90 °C for 48 h.  The mixture was cooled to room temperature, diluted with DCM and filtered through silica, washed with DCM, concentrated under reduced pressure and the crude residue was purified by flash chromatography with EtOAc/hexane or Et2O/hexane (1:20 to 1:10) to give the product. 
 
Methyl benzyl(hex-1-yn-1-yl)carbamate (1d)[Error! Bookmark not defined.] 
Representative Procedure B.  Prepared from methyl benzylcarbamate (6.955 g, 42.1 mmol, 1.0 equiv) and 1-bromohex-1-yne (8.136 g, 50.5 mmol, 1.2 equiv) using K3PO4·H2O (19.39 g. 84.2 mmol, 2.0 equiv), CuSO4·5H2O (2.103 g, 8.42 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (3.338 g, 16.8 mmol, 0.4 eq) and toluene (60 mL) at 80 °C to give the desired product as a pale yellow oil (7.277 g, 29.7 mmol, 70%): 1H NMR (CDCl3, 400 MHz) δ 7.39–7.27 (m, 5H), 4.59 (s, 2H), 3.80 (s, 3H), 2.25 (t, 2H, J = 7.3), 1.43 (qn, 2H, J = 7.3), 1.32 (sx, 2H, J = 7.3), 0.89 (t, 3H, J = 7.3); 13C NMR (CDCl3, 100 MHz) δ 156.4, 136.4, 128.6, 128.0, 73.9, 70.8, 54.1, 31.1, 21.9, 18.3, 13.7, two peaks not observed/overlapped. HRMS (ESI) for C15H20NO2 [M+H]+ found 246.1480, calc. 246.1489. 
 
Ethyl benzyl(hex-1-yn-1-yl)carbamate (1e) 
Representative Procedure B.  Prepared from ethyl benzylcarbamate (5.077 g, 28.3 mmol, 1.0 equiv) and 1-bromohex-1-yne (5.477 g, 34.0 mmol, 1.2 equiv) using K3PO4·H2O (13.05 g. 56.7 mmol, 2.0 equiv), CuSO4·5H2O (1.409 g, 5.67 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.246 g, 11.3 mmol, 0.4 equiv) and toluene (60 mL) at 80 °C to give the desired product as a pale yellow oil (3.9024 g, 15.0 mmol, 53%): 1H NMR (CDCl3, 400 MHz) δ 7.3–7.1 (m, 5H), 4.51 (s, 2H), 4.15 (q, 2H, J = 7.0), 2.17 (t, 2H, J = 6.6), 1.40–1.17 (m, 4H), 0.80 (t, 3H, J = 6.6); 13C NMR (CDCl3, 100 MHz) δ 155.9, 136.6, 128.5, 128.4, 127.9, 74.1, 70.5, 63.1, 53.8, 31.1, 21.9, 18.2, 14.5, 13.7; HRMS (ESI) for C16H22NO2 [M+H]+ found 260.1655, calc. 260.1645. 
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tert-Butyl benzyl(hex-1-yn-1-yl)carbamate (1f) 
Representative Procedure B.  Prepared from tert-butyl benzylcarbamate (4.972 g, 24.0 mmol, 1.0 equiv) and 1-bromohex-1-yne (4.64 g, 28.8 mmol, 1.2 equiv) using K3PO4·H2O (11.05 g. 48.0 mmol, 2.0 equiv), CuSO4·5H2O (1.20 g, 4.80 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.90 g, 9.60 mmol, 0.4 equiv) and toluene (80 mL) at 90 °C to give the desired product as a pale yellow oil (3.833 g, 13.3 mmol, 56%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.20 (m, 5H), 4.50 (s, 2H), 2.20 (m, 2H), 1.50–1.35 (m, 2H), 1.30 (sx, 2H, J = 7.2), 0.83 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 154.7, 137.0, 128.5, 128.2, 127.7, 82.1, 74.9, 69.8, 53.2, 31.1, 28.2, 21.9, 18.2, 13.7; HRMS (ESI) for C18H25NO2Na [M+Na]+ found 310.1776, calc. 310.1783. 
 
Benzyl benzyl(hex-1-yn-1-yl)carbamate (1g) 
Representative Procedure B.  Prepared form benzyl benzylcarbamate (4.3935 g, 18.2 mmol, 1.0 equiv) and 1-bromohex-1-yne (3.5187 g, 21.8 mmol, 1.2 equiv) using K3PO4·H2O (8.386 g, 36.4 mmol, 2.0 equiv), CuSO4·5H2O (0.9093 g, 3.64 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.4437 g, 7.28 mmol, 0.4 equiv) and toluene (40 mL) at 80 °C to give the desired product as a yellow oil 3.6119 g, 11.2 mmol, 62%): 1H NMR (CDCl3, 500 MHz) δ 7.50–7.30 (m, 10 H), 5.30 (s, 2H), 4.69 (s, 2H), 2.31 (m, 2H), 1.55–1.45 (qn, 2H, J = 7.2), 1.45–1.35 (sx, 2H, J = 7.2), 0.94 (t, 3H, J = 7.2); 13C NMR (CDCl3, 125 MHz) δ 155.7, 136.3, 135.9, 128.48, 128.47, 128.4, 128.2, 127.9, 127.7, 73.7, 70.6, 68.3, 53.8, 31.0, 21.8, 18.1, 13.6; HRMS (ESI) for C21H23NO2Na [M+Na]+ found 344.1620, calc. 344.1621.  
 
Methyl (4-chlorophenyl)(hex-1-yn-1-yl)carbamate (1h) 
Representative Procedure B.  Prepared from methyl (4-chlorophenyl)carbamate (5.466 g, 29.5 mmol, 1.0 equiv) and 1-bromohex-1-yne (5.69 g, 35.3 mmol, 1.2 equiv) using K3PO4·H2O (13.56 g, 58.9 mmol, 2.4 equiv), CuSO4·5H2O (1.471 g, 5.89 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (2.335 g, 11.8 mmol, 0.4 equiv) and toluene (60 mL) at 80 °C to give the desired product as an organge oil (4.585 g, 17.3 mmol, 59%): 1H NMR (CDCl3, 400 MHz) δ 7.39 (d, 2H, J = 8.6), 7.28 (d, 2H, J = 8.6), 3.81 (s, 3H), 2.29 (t, 2H, J = 6.9), 1.48 (qn, 2H, J = 6.9), 1.38 (sx, 2H, J = 6.9), 0.87 (t, 3H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 155.1, 138.7, 132.1, 129.0, 125.6, 73.3, 70.5, 64.4, 31.0, 22.1, 18.2, 13.7; HRMS for C14H17ClNO2 [M+H]+ found 266.0932, calc. 266.0942. 
 
Methyl benzyl(oct-1-yn-1-yl)carbamate (1i)[Error! Bookmark not defined.] 
Representative Procedure B.  Prepared using methyl benzylcarbamate (6.465 g, 39.1 mmol, 1.0 equiv) and 1-bromooct-1-yne (8.880 g, 47.0 mmol, 1.2 equiv) using K3PO4·H2O (18.02 g, 78.3 mmol, 2.0 equiv), CuSO4·5H2O (1.954 g, 7.83 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (3.103 g, 15.7 mmol, 0.4 equiv) and toluene (60 mL) at 100 °C to give the desired product as a yellow oil (6.2891 g, 23.0 mmol, 59%): 1H NMR (CDCl3, 400 MHz) δ 2.19 (t, 2H, J = 7.0), 1.51 (qn, 2H, J = 7.0), 1.42–1.20 (m, 6H), 0.89 (3H, t, J = 7.0); 13C NMR (CDCl3, 100 MHz) δ 156.3, 136.4, 128.5, 128.4, 127.9, 73.9, 70.7, 54.0, 53.5, 31.4, 29.0, 28.5, 22.7, 18.5, 14.1. HRMS (ESI) for C17H24NO2 [M+H]+ found 274.1798, calc. 274.1802. 
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Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)carbamate (1j) 
Representative Procedure B.  Prepared from methyl benzylcarbamate (2.197 g, 13.3 mmol, 1.0 equiv) and ((4-bromobut-3-yn-1-yl)oxy)(tert-butyl)dimethylsilane (4.2021 g, 16.0 mmol, 1.2 equiv) using K3PO4·H2O (7.352 g, 31.9 mmol, 2.4 equiv), CuSO4·5H2O (0.664 g, 2.66 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.0545 g, 5.32 mmol, 0.4 equiv) and toluene (50 mL) at 100 °C to give the desired product as a yellow oil (2.4914 g, 7.17 mmol, 54%) of product.  Yellow oil: 1H NMR (CDCl3, 400 MHz) δ 7.35–7.20 (m, 5H), 4.54 (s, 2H), 3.74 (s,3H), 3.60 (d, 2H, J = 7.1), 2.42 (d, 2H, J = 7.1), 0.84 (s, 9H), 0.00 (s, 6H); 13C NMR (CDCl3, 100 MHz) δ 156.2, 136.3, 128.5, 128.4, 128.0, 74.8, 67.6, 62.2, 54.0, 26.0, 22.9, 18.4, -5.24, one carbon not observed (PhCH2); HRMS (ESI) for C19H30NO3Si [M+H]+ found 348.1990, calc. 348.1989. 
 
Methyl benzyl(phenylethynyl)carbamate (1k)[8] 
Representative Procedure B.  Prepared from methyl benzylcarbamate (3.1557 g, 19.1 mmol, 1.0 equiv) and (bromoethynyl)benzene (4.1500 g, 22.9 mmol, 1.2 equiv) using K3PO4·H2O (8.798 g, 38.2 mmol, 2.0 equiv), CuSO4·5H2O (0.9540 g, 3.82 mmol, 0.2 equiv), 1,10-phenanthroline monohydrate (1.5147 g, 7.64 mmol, 0.4 equiv) and toluene (60 mL) at 100 °C to give the desired product as a yellow oil (3.660 g, 13.8 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.50–7.20 (m, 10H), 4.76 (s, 2H), 3.89 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.7, 136.0, 131.3, 128.7, 128.3, 128.2, 127.7, 123.2, 83.1, 71.3, 54.3, 54.2, one carbon not observed (Ar). HRMS (ESI) for C17H16NO2 [M+H]+ found 266.1156, calc. 266.1176. 
 
3-(Prop-1-yn-1-yl)oxazolidin-2-one (1b):[9] 
Procedure C [Evano N-alkynylation using alkynylcopper reagent]:[10] A slurry of oxazolidin-2-one (5.930 g, 67.8 mmol, 1.5 equiv), prop-1-yn-1-ylcopper (4.64 g, 45.2 mmol, 1.0 equiv), and TMEDA (6.81 mL, 45.2 mmol 1.0 equiv) in acetonitrile (20 mL) was stirred at RT for 48 h under dioxygen atmosphere (balloon).  The mixture was filtered through a short silica plug, washed with DCM, concentrated under reduced pressure and the crude residue was purified by flash chromatography with EtOAc/hexane (1:5) to give the product as a colourless oil (4.1232 g, 33.0 mmol, 73%): 1H NMR (CDCl3, 400 MHz) δ 4.32 (t, 2H, J = 7.8), 3.78 (t, 2H, J = 7.8), 1.82 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 156.7, 69.0, 66.3, 62.9, 46.7, 2.9. HRMS (ESI) for C6H8NO2 [M+H]+ found 126.0553, calc. 126.0550. 
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3-(Hex-1-yn-1-yl)benzo[d]oxazol-2(3H)-one (1c) 
Procedure D [Evano N-alkynylation using potassium alkynyltrifluoroborates]:[11] A slurry of potassium 1-hexynyltrifluoroborate (6.589 g, 35.0 mmol, 1 equiv), 2-benzoxazolinone (9.470 g, 70.1 mmol, 2 equiv), 1,2-dimethylimidazole (1.24 mL, 14.0, 0.2 equiv), CuCl2-2H2O (1.20 g, 7.01 mmol, 0.1 equiv) was stirred in DCM (20 mL) under dioxygen atmosphere (balloon) at 37 oC for 48 h.  The solvent was removed under reduced pressure and the residue was purified by flash chromatography (EtOAc/Hex 1:40) to give the product as a yellow oil (1.5354 g, 7.13 mmol. 20%): 1H NMR (CDCl3, 400 MHz) δ 7.2–7.0 (m, 4H, ArH), 2.40 (t, 2H, J = 7.0, CH2C≡C), 1.55 (qn, 2H, J = 7.0, CH2CH2C≡C), 1.43 (sx, 2H, J = 7.0, CH3CH2), 0.88 (t, 2H, J = 7.0, CH3); 13C NMR (CDCl3, 100 MHz) δ 153.0, 142.0, 130.0, 124.5, 124.1, 110.3, 110.1, 76.6, 64.9, 30.5, 21.9, 18.2, 13.6; HRMS for C13H14NO2 [M+H]+ found 216.1022, calc. 216.1019. 
 
3.2  Formation of Stereodefined Enolates 
  
 
3.2.1  One-Pot Procedure using Gilman Reagents 
Representative Procedure E 
A solution of MeLi in Et2O (2–2.4 equiv) was added dropwise to a suspension of CuBr·DMS (1.0–1.1 equiv) in Et2O (15–30 mL) at –30 °C.  Once the solution became colourless (after 10 min), a solution of ynecarbamate (1.0 equiv) in Et2O (5–10 mL) was added and the mixture left to stir gradually warming up to –10 °C.  When carbometallation was complete (30 min), the mixture was cooled down to –80 °C and ca. 5.5 M tBuOOH (TBHP) solution in decane (1.0 equiv) was added dropwise and left to stir at –80 °C.  After 30 min, allyl chloroformate (2.5–4.0 equiv) was added and the reaction mixture was allowed to warm to room temperature.  It was quenched with 1 M HCl solution, extracted with Et2O (2×), the combined organic layers were dried over MgSO4, filtered, concentrated and purified by flash chromatography (EtOAc/hexane 1:10) to give the desired product. 
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(E)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3a) 
Representative Procedure E.  Prepared from 3-(hex-1-yn-1-yl)oxazolidin-2-one (1.784 g, 10.7 mmol, 1 equiv) using MeLi (1.6 M in Et2O; 13.33 mL, 21.3 mmol, 2 equiv), CuBr·DMS (2.1934 g, 10.7 mmol, 1 equiv), TBHP (5.5 M in decane; 1.94 mL, 10.7 mmol, 1 equiv) and AllocCl (2.84 mL, 26.7 mmol, 2.5 equiv) to give the desired product as a pale yellow oil (2.101 g, 7.42 mmol, 70%): 1H NMR (CDCl3, 400 MHz) δ 5.93 (ddt, 1H, J = 16.6, 10.4, 5.7), 5.37 (d, 1H, J = 16.6), 5.28 (d, 1H, J = 10.4), 4.65 (d, 2H, J = 5.7), 4.37 (t, 2H, J = 7.9), 3.77 (t, 2H, J = 7.9), 2.05 (t, 2H, J = 7.0), 1.68 (s, 3H), 1.42 (qn, 2H, J = 7.0), 1.29 (sx, 2H, J = 7.0), 0.88 (t, 3H, J = 7.0); 13C NMR (CDCl3, 100 MHz) δ 154.6, 152.6, 131.0, 130.1, 125.8, 118.7, 68.4, 61.7, 44.3, 30.1, 28.3, 21.6, 15.2, 13.0. HRMS for C14H22NO5 [M+H]+ found 284.1490, calc. 284.1492. 
 
(Z)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3b) 
Representative Procedure E.  Prepared from 3-(prop-1-yn-1-yl)oxazolidin-2-one (1.6736 g, 13.4 mmol, 1 equiv) using BuLi (1.6 M in hexanes; 16.7 mL, 26.7 mmol, 2 equiv), CuBr·DMS (2.750 g, 13.4 mmol, 1 equiv), TBHP (5.5 M in decane; 2.43 mL, 13.4 mmol, 1 equiv) and AllocCl (3.55 mL, 33.4 mmol, 2.5 equiv) to give the desired product as a yellow oil (1.964 g, 6.93 mmol, 52%): 1H NMR (CDCl3, 400 MHz) δ 5.95 (ddt, 1H, J = 17.2, 10.4, 5.8), 5.40 (d, 1H, J = 17.2), 5.30 (dd, 1H, J = 10.4, 1.3), 4.68 (d, 2H, J = 5.8), 4.40 (t, 2H, J = 7.8), 3.82 (t, 2H, J = 7.8), 2.08 (t, 2H, J = 7.2), 1.71 (s, 3H), 1.42 (qn, 2H, J = 7.2), 1.32 (sx, 2H, J = 7.2), 0.90 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 154.6, 152.6, 131.0, 130.1, 125.8, 118.7, 68.4, 61.7, 44.3, 30.1, 28.3, 21.6, 15.2, 13.0; HRMS for C14H22NO5 [M+H]+ found 284.1495, calc. 284.1492. 
 
(E)-Allyl (2-methyl-1-(2-oxobenzo[d]oxazol-3(2H)-yl)hex-1-en-1-yl) carbonate (3c) 
Representative Procedure E.  Prepared from 3-(hex-1-yn-1-yl)benzo[d]oxazol-2(3H)-one (130 g, 0.604 mmol, 1 equiv) using MeLi (1.6 M in Et2O; 906 µL, 1.45 mmol, 2.4 equiv), CuBr·DMS (150 mg, 0.730 mmol, 1.2 equiv), TBHP (5.5 M in decane; 132 µL, 0.730 mmol, 1.2 equiv) and AllocCl (257 µL, 2.42 mmol, 4 equiv) to give the desired product as a yellow oil (97.6 mg, 0.295 mmol, 49%): 1H NMR (CDCl3, 500 MHz) δ 7.22–7.12 (m, 4H), 5.89 (ddt, 1H, J = 17.3, 10.5, 5.8), 5.34 (dqt, 1H, J = 17.3, 1.3), 5.26 (dqt, 1H, J = 10.5, 1.23), 4.62 (dqt, 2H, J = 5.8, 1.3), 2.00 (td, 2H, J = 7.6, 3.6), 1.88 (s, 3H), 1.50–1.30 (m, 2H), 1.21 (sx, 2H, J = 7.5), 0.79 (t, 3H, J = 7.5); 
13C NMR (CDCl3, 125 MHz) δ 152.6, 152.4, 142.7, 131.0, 130.8, 130.5, 128.0, 124.2, 123.4, 119.7, 110.8, 110.3, 69.6, 31.8, 29.2, 22.4, 15.5, 13.8; HRMS (APCI) for C18H22NO5 [M+H]+ found 332.1515, calc. 332.1492. 
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3.2.2  Two-Step Procedure Using Grignard Reagents 
3.2.2.1  Carbometallation–Iodination Products 
Representative Procedure F 
Carbometallation–Iodination: A solution of ynecarbamate (1 equiv) in Et2O (5–10 mL) was added to a suspension of CuI (1 equiv) and RMgBr (in Et2O; 2 equiv) in Et2O (15–25 mL) at – 30 °C and the mixture was left to stir gradually warming up to –10 °C.  After 1 h, a solution of iodine (2 equiv) in THF (10–20 mL) was added dropwise at –10 °C and the mixture left for 15 min.  It was then quenched with sat. aq. Na2S2O3 solution and extracted with Et2O (2×), the combined organic layers were dried over MgSO4, filtered, concentrated and purified by flash chromatography Et2O/hexane or Et2O/pentane (1:20 to 1:10) to give the desired product. 
 
(E)-Methyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4d) 
Representative Procedure F.  Prepared from methyl benzyl(hex-1-yn-1-yl)carbamate (200 mg, 0.815 mmol, 1 equiv) using CuI (155 mg, 0.815 mmol, 1 equiv), MeMgBr (3 M in Et2O; 0.69 mL, 1.63 mmol, 2 equiv) and iodine (424 mg, 1.63 mmol, 2 equiv) to give the desired product as a pale yellow oil (316 mg, 0.815 mmol, quant): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.25 (m, 5H), 4.98 (d, 1H, J = 14.2), 4.05 (d, 1H, J = 14.2), 3.81 (s, 3H), 1.77 (s, 3H), 1.70 (td, 1H, J = 13.2, 5.2), 1.55 (m, 1H), 1.15–1.05 (m, 1H), 1.05–0.90 (m, 2H), 0.73 (t, 3H, J = 7.2), 0.65–0.50 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 155.5, 146.2, 135.8, 129.9, 128.3, 127.8, 95.3, 53.6, 52.2, 33.5, 29.1, 25.9, 22.7, 13.8; HRMS (APCI) for C20H31INO2 [M+H]+ found 338.0770, calc. 338.0768. 
 
(E)-Ethyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4e) 
Representative Procedure F.  Prepared from ethyl benzyl(hex-1-yn-1-yl)carbamate (1.5237 g, 5.88 mmol, 1 equiv) using CuI (1.119 g, 5.88 mmol, 1 equiv), MeMgBr (3 M in Et2O; 3.92 mL, 11.8 mmol, 2 equiv) and iodine (2.982 mg, 11.8 mmol, 2 equiv) to give the desired product as a yellow oil (1.728 g, 4.31 mmol, 73%): 1H NMR (CDCl3, 300 MHz) δ 7.31–7.13 (m, 5H), 4.87 (d, 1H, J = 14.2), 4.24–4.07 (m, 2H), 3.91 (d, 1H, J = 14.2), 1.69 (s, 3H), 1.63–1.53 (m, 1H), 1.57–1.37 (m, 1H), 1.20 (m, 3H, J = 7.0), 0.62 (t, 3H, J = 7.2), 0.50–0.33 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 155.0, 145.8, 135.9, 129.9, 128.3, 127.7, 95.7, 62.4, 52.0, 33.5, 29.2, 25.8, 22.7, 14.7, 13.8; HRMS for C17H25INO2 [M+H]+ found 402.0975, calc. 402.0924. 
 
(E)-tert-Butyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4f) 
Representative Procedure F.  Prepared from tert-butyl benzyl(hex-1-yn-1-yl)carbamate (1.022 g, 3.56 mmol, 1 equiv) using CuI (0.677 g, 3.56 mmol, 1 equiv), MeMgBr (3 M in Et2O; 2.37 mL, 7.11 mmol, 2 equiv) and iodine (1.805 g, 7.11 mmol, 2 equiv) to give the desired product as a pale yellow oil (1.1732 g, 2.73 mmol, 77%): 1H NMR (CDCl3, 400 MHz) δ 7.30–7.10 (m, 5H), 4.80 (d, 1H, J = 13.9), 3.83 (d, 1H, J = 13.9), 1.65–1.55 (m, 4H), 1.40 (s, 9H), 1.10–0.95 (m, 1H), 0.89 (qn, 2H, J = 7.2), 0.85–0.75 (m, 1H), 0.63 (t, 3H, J = 7.2), 0.55–0.45 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 153.7, 144.7, 136.2, 129.8, 128.1, 127.5, 97.4, 80.9, 51.6, 33.4, 29.1, 28.2, 25.7, 22.7, 13.7; HRMS (APCI) for C19H29INO2 [M+H]+ found 430.1217, calc. 430.1237. 
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(E)-Benzyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4g) 
Representative Procedure F.  Prepared from benzyl benzyl(hex-1-yn-1-yl)carbamate (0.618 g, 1.92 mmol, 1 equiv) using CuI (0.366 g, 1.92 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.28 mL, 3.85 mmol, 2 equiv) and iodine (0.976 g, 3.85 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.891 g, 1.92 mmol, quant): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 10H), 5.20–5.05 (m, 2H), 4.90 (d, 1H, J = 13.9), 3.95 (d, 1H, J =13.9), 1.64 (s, 3H), 1.60-1.45 (m, 2H), 1.00–0.65 (m, 3H), 0.60–0.50 (m, 3H), 0.40–0.25 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 154.9, 146.3, 136.3, 135.7, 129.9, 128.4, 128.3, 128.0, 127.8, 95.0, 68.0, 52.2, 33.6, 29.1, 25.8, 22.7, 13.7, one carbon not observed (Ar); HRMS (APCI) for C22H27INO2 [M+H]+ found 464.1073, calc. 464.1081. 
 
(E)-Methyl (4-chlorophenyl)(2-methyl-1-iodohex-1-en-1-yl)carbamate (4h) 
Representative Procedure F.  Prepared from benzyl methyl (4-chlorophenyl)(hex-1-yn-1-yl)carbamate (0.710 g, 2.67 mmol, 1 equiv) using CuI (0.509 g, 2.67 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.78 mL, 5.34 mmol, 2 equiv) and iodine (1.356 g, 5.34 mmol, 2 equiv) to give the desired product as a yellow oil (0.949 g, 2.33 mmol, 87%): 1H NMR (CDCl3, 500 MHz) δ 7.40–7.30 (m, 4H), 3.83 (s, 3H), 2.35–2.25 (m, 1H), 2.18 (td, 1H, J = 10.3, 4.4), 1.94 (s, 3H), 1.45–1.35 (m, 1H), 1.35–1.15 (m, 3H), 0.88 (t, 3H, J = 7.2); 13C NMR (CDCl3, 125 MHz) δ 154.0, 146.6, 139.1, 131.5, 128.9, 125.5, 92.9, 53.7, 33.4, 29.2, 26.1, 22.8, 13.9; HRMS (ESI) for C15H20ClNIO2 [M+H]+ found 408.0221, calc. 408.0222. 
 
(E)-Methyl benzyl(1-iodo-2-methyloct-1-en-1-yl)carbamate (4i) 
Representative Procedure F.  Prepared from methyl benzyl(oct-1-yn-1-yl)carbamate (0.675 g, 2.47 mmol, 1 equiv) using CuI (0.470 g, 2.47 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.65 mL, 4.94 mmol, 2 equiv) and iodine (1.253 g, 4.94 mmol, 2 equiv) to give the desired product as a pale yellow oil (1.025 g, 2.47 mmol, quant): 1H NMR (CDCl3, 400 MHz) δ 7.46–7.10 (m, 5H), 4.87 (d, 1H, J = 14.0), 3.93 (d, 1H, J = 14.0), 3.68 (s, 3H), 1.66 (s, 3H), 1.59 (td, 1H, J = 12.0, 5.5), 1.50–1.36 (m, 1H), 1.10 (qn, 2H, J = 7.2), 1.05–0.91 (m, 3H), 0.87–0.78 (m, 2H), 0.76 (t, 3H, J =7.2), 0.53–0.37 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 155.5, 146.1, 135.7, 129.9, 128.3, 127.8, 95.3, 53.6, 52.2, 33.7, 31.5, 29.3, 27.0, 25.8, 22.5, 14.1; HRMS (APCI) for C18H27INO2 [M+H]+ found 416.1083, calc. 416.1081. 
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(E)-Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)-1-iodo-2-methylbut-1-en-1-yl)carbamate (4j) 
Representative Procedure F.  Prepared from methyl benzyl(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)carbamate (0.542 g, 1.56 mmol, 1 equiv) using CuI (0.297 g, 1.56 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.04 mL, 3.12 mmol, 2 equiv) and iodine (0.792 g, 3.12 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.703 g, 1.44 mmol, 92%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.20 (m, 5H), 4.95 (d, 1H, J =13.9), 4.12 (d, 1H, J = 13.9), 3.81 (s, 3H), 3.30–3.10 (m, 2H), 2.10–2.00 (m, 2H), 1.92–1.78 (m, 4H), 0.88 (s, 9H), 0.0074 (s, 3H), –0.0001 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.4, 143.4, 135.4, 130.0, 128.3, 127.9, 97.1, 60.8, 53.6, 52.6, 36.9, 26.6, 25.9, 18.2, –5.35l; HRMS (APCI) for C20H33INO3Si [M+H]+ found 490.1282, calc. 490.1269. 
 
(E)-Methyl benzyl(1-iodo-2-phenylprop-1-en-1-yl)carbamate (4k) 
Representative Procedure F.  Prepared from methyl benzyl(phenylethynyl)carbamate (0.500 g, 1.88 mmol, 1 equiv) using CuI (0.359 g, 1.88 mmol, 1 equiv), MeMgBr (3 M in Et2O; 1.26 mL, 3.77 mmol, 2 equiv) and iodine (0.957 g, 3.77 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.551 g, 1.35 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.20–6.95 (m, 6H), 6.95–6.80 (m, 2H), 6.70–6.50 (m, 2H), 4.31 (d, 1H, J = 13.9), 4.04 (d, 1H, J =13.9), 3.71 (s, 3H), 2.03 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 155.8, 144.8, 139.4, 134.8, 129.6, 128.1, 127.4, 127.1, 126.6, 98.1, 53.6, 53.1, 29.6, one carbon not observed (overlapped in Ar); HRMS (APCI) for C18H19INO2 [M+H]+ found 408.0447, calc. 408.0455. 
 
(E)-Methyl benzyl(2-ethyl-1-iodohex-1-en-1-yl)carbamate (4l) 
Representative Procedure F.  Prepared from methyl benzyl(hex-1-yn-1-yl)carbamate (0.471 g, 1.92 mmol, 1 equiv) using CuI (0.366 g, 1.92 mmol, 1 equiv), EtMgBr (1.9 M in Et2O; 2.02 mL, 3.84 mmol, 2 equiv) and iodine (0.975 g, 3.84 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.564 g, 1.41 mmol, 73%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.15 (m, 5H), 4.89 (d, 1H, J = 13.8), 3.92 (d, 1H, J = 13.8), 3.69 (s, 3H), 2.12–2.02 (m, 1H), 2.02–1.90 (m, 1H), 1.58 (td, 1H, J = 13.3, 4.8), 1.45–1.35 (m, 1H), 1.05–0.85 (m, 3H), 0.81 (t, 3H, J = 7.4), 0.63 (t, 3H, J = 7.2), 0.55–0.45 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 155.6, 150.9, 135.6, 130.2, 128.4, 127.9, 94.9, 53.6, 52.1, 31.7, 31.0, 29.3, 22.9, 13.8, 11.6; HRMS (APCI) for C17H25INO2 [M+H]+ found 402.0911, calc. 402.0924. 
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(E)-Methyl benzyl(2-ethyl-1-iodooct-1-en-1-yl)carbamate (4m) 
Representative Procedure F.  Prepared from methyl benzyl(oct-1-yn-1-yl)carbamate (0.464 g, 1.69 mmol, 1 equiv) using CuI (0.323 g, 1.69 mmol, 1 equiv), EtMgBr (1.9 M in Et2O; 1.78 mL, 3.39 mmol, 2 equiv) and iodine (0.860 g, 3.39 mmol, 2 equiv) to give the desired product as a pale yellow oil (0.621 g, 1.45 mmol, 85%): 1H NMR (CDCl3, 500 MHz) δ 7.40–7.25 (m, 5H), 4.98 (d, 1H, J = 13.5), 4.02 (d, 1H, J = 13.5), 3.79 (s, 3H), 2.25–2.15 (m, 1H), 2.15–2.05 (m, 1H), 1.68 (td, 1H, J =13.1, 4.9), 1.55–1.40 (m, 1H), 1.30–1.25 (m, 2H), 1.15–0.90 (m, 5H), 0.90 (t, 3H, J = 7.4), 0.87 (t, 3H, J = 7.3), 0.70–0.60 (m, 1H); 13C NMR (CDCl3, 125 MHz) δ 150.9, 135.6, 130.2, 128.3, 127.9, 53.6, 52.1, 31.7, 31.6, 31.3, 29.5, 27.1, 22.6, 14.2, 11.7, two carbons not observed (C=C); HRMS (APCI) for C19H29INO2 [M+H]+ found 430.1237, calc. 430.1240. 
 
Methyl (Z)-benzyl(1-iodo-2-(3-phenylpropyl)oct-1-en-1-yl)carbamate (4n) 
Representative Procedure F.  Prepared from methyl benzyl(oct-1-yn-1-yl)carbamate (1.029 g, 3.76 mmol, 1 equiv) using CuI (0.717 g, 3.76 mmol, 1 equiv), Ph(CH2)3MgBr (2.3 M in Et2O; 3.27 mL, 7.53 mmol, 2 equiv) and iodine (1.911 g, 7.53 mmol, 2 equiv) to give the desired product as a yellow oil (1.801 g, 3.47 mmol, 92%): 1H NMR (CDCl3, 500 MHz) δ 7.41–7.37 (m, 2H), 7.37–7.29 (m, 5H), 7.26–7.20 (m, 3H), 5.05 (br d, 1H, J = 13.5), 4.05 (br d, 1H, J = 13.5), 3.82 (s, 3H), 2.64 (td, J = 7.6, 1.6), 2.27–2.10 (m, 2H), 1.77–1.60 (m, 2H), 1.58–1.48 (br s, 1H), 1.24 (qn, 2H, J = 7.4), 1.13–0.92 (m, 6H), 0.90 (m, 3H, J = 7.4), 0.63–0.52 (m, 1H); 13C NMR (CDCl3, 125 MHz) δ 155.6, 149.4, 142.1, 135.6, 130.1, 128.5, 128.37, 128.35, 127.9, 125.9, 95.8, 53.6, 52.1, 37.9, 35.7, 31.6, 31.5, 29.4, 28.9, 27.1, 22.6, 14.2; HRMS (APCI) for C26H35INO2 [M+H]+ found 520.1711, calc. 520.1707. 
 
(E)-3-(2-Ethyl-1-iodohex-1-en-1-yl)oxazolidin-2-one (4o) 
Representative Procedure F.  Prepared from 3-(hex-1-yn-1-yl)oxazolidin-2-one (0.920 g, 5.50 mmol, 1 equiv) using CuI (1.049 g, 5.50 mmol, 1 equiv), EtMgBr (2.7 M in Et2O; 4.08 mL, 11.0 mmol, 2 equiv) and iodine (2.793 g, 11.0 mmol, 2 equiv) to give the desired product as a yellow oil (1.630 g, 5.04 mmol, 92%): 1H NMR (CDCl3, 300 MHz) δ 4.45–4.25 (m, 2H), 3.64 (q, 1H, J = 9.5), 3.40–3.25 (m, 1H), 2.30–2.10 (m, 4H), 1.50–1.15 (m, 4H), 1.00 (t, 3H, J = 7.3), 0.85 (t, 3H, J = 7.3); 13C NMR (CDCl3, 75 MHz) δ 155.8, 153.5, 90.1, 62.0, 46.6, 32.0, 31.3, 30.1, 22.7, 13.8, 11.7; HRMS (ESI) for C11H19INO2 [M+H]+ found 324.0450, calc. 324.0455. 
 
(E)-3-(2-Ethyl-1-iodooct-1-en-1-yl)oxazolidin-2-one (4p) 
Representative Procedure F.  Prepared from 3-(oct-1-yn-1-yl)oxazolidin-2-one (0.9911 g, 5.08 mmol, 1 equiv) using CuI (0.9667 g, 5.08 mmol, 1 equiv), EtMgBr (2.7 M in Et2O; 3.76 mL, 10.15 mmol, 2 equiv) and iodine (2.577 g, 10.15 mmol, 2 equiv) to give the desired product as a yellow oil (1.5244 g, 4.34 mmol, 86%): 1H NMR (CDCl3, 300 MHz) δ 4.42–4.24 (m, 2H), 3.63 (q, 1H, J = 9.5), 3.35–3.23 (m, 1H), 2.22–2.06 (m, 4H), 1.47–1.24 (m, 2H), 1.24–1.12 (m, 8H), 0.97 (t, 3H, J = 7.3), 0.80 (t, 3H, J = 7.3); 13C NMR (CDCl3, 75 MHz) δ 155.7, 153.3, 90.1, 62.0, 46.5, 31.9, 31.5, 31.4, 29.2, 27.8, 22.4, 14.0, 11.6; HRMS (ESI) for C13H23INO2 [M+H]+ found 352.0740, calc. 352.0768. 
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3.2.2.2  Regioretentive Formation of Alloc-Trapped Products 
Representative Procedure G 
Representative Procedure for Regioretentive Formation of Alloc-Trapped Products: A solution of MeLi in Et2O (2.1 equiv) was added dropwise to a solution of tBuOOH (5.5 M in decane; 1.8 equiv) in THF (15 mL) at –80 °C.  After the addition of base was complete, the mixture was stirred for additional 15–30 min prior to be used as an in situ prepared oxidant.  
A solution of tBuLi in hexane (2.1 equiv) was added dropwise to a solution of vinyl iodide 5 (1 equiv) in Et2O at –80 °C.  After 15 min, a solution of freshly prepared tBuOOLi (see above; ca. 1.5 equiv) was added via syringe at –80 °C and the mixture was left to stir warming up to –40 °C.  After 1 h, AllocCl (4.5 equiv) was added and the reaction mixture was allowed to warm to room temperature.  It was quenched with 1 M HCl solution, extracted with Et2O (2×), the combined organic layers were dried over MgSO4, filtered, concentrated and purified by flash chromatography (Et2O/hexane or EtOAc/hexane) to give the desired product. 
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3d) 
Representative Procedure G.  Prepared from vinyl iodide 4d (1.611 g, 4.16 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 4.89 mL, 8.32 mmol, 2.0 equiv), TBHP (5.5 M in decane; 1.51 mL, 8.32 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 5.98 mL, 9.57 mmol, 2.3 equiv) and AllocCl (1.77 µL, 16.64 mmol, 4.0 equiv) to give the desired product as a yellow oil (1.082 g, 2.99 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.4–7.10 (m, 5H), 5.83 (ddt, 1H, J = 17.2, 10.4, 5.5), 5.30 (d, 1H, J = 17.2), 5.22 (d, 1H, J = 10.4), 4.66 (d, 1H, J = 14.6), 4.51 (d, 2H, J = 5.5), 4.41 (d, 1H, J = 14.6), 3.71 (s, 3H), 1.75–1.60 (m, 2H), 1.55 (s, 3H), 1.10–0.90 (m, 2H), 0.90–0.75 (m, 2H), 0.72 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.3, 152.7, 137.5, 134.8, 131.2, 128.8, 128.3, 127.4, 126.1, 119.2, 68.9, 53.3, 51.2, 32.0, 28.9, 22.7, 14.9, 13.9; HRMS (ESI) for C20H28NO5 [M+H]+ found 362.1960, calc. 362.1962. 
 
(E)-Ethyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3e) 
Representative Procedure G.  Prepared from vinyl iodide 4e (0.879 g, 2.19 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 2.58 mL, 4.38 mmol, 2.0 equiv), TBHP (5.5 M in decane; 797 µL, 4.38 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 3.15 mL, 5.04 mmol, 2.3 equiv) and AllocCl (916 µL, 8.76 mmol, 4.0 equiv) to give the desired product as a yellow oil (0.632 g, 1.68 mmol, 77%): 1H NMR (CDCl3, 400 MHz) δ 7.45–7.10 (m, 5H), 5.81 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.28 (d, 1H, J = 17.2), 5.20 (d, 1H, J = 10.4), 4.67 (d, 1H, J = 14.6), 4.49 (d, 2H, J = 5.7), 4.38 (d, 1H, J = 14.6), 4.20–4.05 (m, 2H), 1.70–1.57 (m, 2H), 1.51 (s, 3H), 1.18 (t, 3H, J = 7.1), 1.05–0.90 (m, 2H), 0.90–0.75 (m, 2H), 0.70 (t, 3H, J = 7.1); 13C NMR (CDCl3, 100 MHz) δ 155.8, 152.8, 137.7, 135.0, 131.3, 128.8, 128.3, 127.4, 125.9, 119.2, 68.9, 62.2, 51.1, 32.1, 29.0, 22.7, 14.9, 14.6, 13.9; HRMS (ESI) for C21H30NO5 [M+H]+ found 376.2097, calc. 376.2118. 
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(E)-tert-Butyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3f)  
Representative Procedure G.  Prepared from vinyl iodide 4f (0.300 g, 0.70 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 822 µL, 1.40 mmol, 2.0 equiv), TBHP (5.5 M in decane; 254 µL, 1.40 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 1.00 mL, 1.61 mmol, 2.3 equiv) and AllocCl (334 µL, 3.14 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.230 g, 0.57 mmol, 82%): 1H NMR (CDCl3, 400 MHz) δ 7.45–7.10 (m, 5H), 5.81 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.27 (d, 1H, J = 17.2), 5.18 (d, 1H, J = 10.4), 4.67 (br s, 1H), 4.48 (d, 2H, J = 5.6), 4.33 (d, 1H, J = 14.5), 1.7–1.55 (m, 2H), 1.54 (s, 3H), 1.38 (s, 9H), 1.25–0.80 (m, 4H), 0.70 (t, 3H, J = 7.0); 13C NMR (CDCl3, 125 MHz) δ NMR 154.7, 152.9, 138.1, 135.5, 131.4, 128.7, 128.3, 127.2, 119.2, 80.8, 77.4, 68.9, 50.5, 32.3, 29.1, 28.3, 22.8, 14.0; HRMS (ESI) for C23H34NO5 [M+H]+ found 404.2433, calc. 404.2431. 
 
(E)-Benzyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3g) 
Representative Procedure G.  Prepared from vinyl iodide 4g (0.517 g, 1.12 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.40 mL, 2.23 mmol, 2.0 equiv), TBHP (5.5 M in decane; 365 µL, 2.01 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 1.89 mL, 2.34 mmol, 2.1 equiv) and AllocCl (534 µL, 5.02 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.383 g, 0.875, 78%): 1H NMR (CDCl3, 500 MHz) δ 7.45–7.10 (m, 10H), 5.79 (ddt, 1H, J = 17.1, 10.4, 5.7), 5.26 (dd, 1H, J = 17.1, 1.3), 5.19 (d, 1H, J = 10.4), 5.20–5.10 (m, 2H), 4.64 (br d, 1H, J = 14.6), 4.47 (d, 1H, J =5.7), 4.40 (br d, 1H, J = 14.6), 1.60–1.45 (m, 5H), 1.10–0.75 (m, 4H), 0.75–0.55 (m, 3H); 13C NMR (CDCl3, 125 MHz) δ 155.7, 152.8, 137.5, 136.4, 134.7, 131.3, 128.8, 128.4, 128.3, 128.0, 127.9, 127.4, 126.2, 119.2, 69.0, 67.9, 51.3, 32.2, 28.9, 22.7, 15.0, 13.9; HRMS (ESI) for C26H32NO5 [M+H]+ found 438.2269, calc. 438.2275. 
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(4-chlorophenyl)carbamate (3h) 
Representative Procedure G.  Prepared from vinyl iodide 4h (0.909 g, 2.23 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 2.79 mL, 4.46 mmol, 2.0 equiv), TBHP (5.5 M in decane; 0.730 mL, 4.01 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 3.78 mL, 4.68 mmol, 2.1 equiv) and AllocCl (1.07 mL, 10.0 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.610 g, 1.60 mmol, 72%): 1H NMR (CDCl3, 400 MHz) δ 7.30–7.15 (m, 4H), 5.79 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.23 (dd, 1H, J = 17.2, 1.2), 5.17 (d, 1H, J = 10.4), 4.51 (d, 2H, J = 5.7), 2.00 (t, 2H, J = 7.2), 1.61 (s, 3H), 1.35–1.10 (m, 4H), 0.79 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 154.6, 152.0, 138.6, 135.0, 131.8, 131.1, 128.9, 126.7, 126.0, 119.3, 68.9, 53.5, 32.2, 28.8, 22.8, 15.4, 14.0; HRMS (ESI) for C19H25ClNO5 [M+H]+ found 382.1441, calc. 382.1416. 
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(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methyloct-1-en-1-yl)(benzyl)carbamate (3i) 
Representative Procedure G.  Prepared from vinyl iodide 4i (0.509 g, 1.23 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.53 mL, 2.45 mmol, 2.0 equiv), TBHP (5.5 M in decane; 401 µL, 2.21 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 2.08 mL, 2.57 mmol, 2.1 equiv) and AllocCl (586 µL, 5.52 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.387 g, 0.99 mmol, 81%): 1H NMR (CDCl3, 400 MHz) δ 7.35–7.10 (m, 5H), 5.79 (ddt, 1H, J = 17.1, 10.4, 5.7), 5.26 (dd, 1H, J = 17.1, 1.2), 5.18 (d, 1H, J = 10.4), 4.63 (br d, 2H, J = 14.5), 4.47 (d, 1H, J = 5.7), 4.37 (br d, J = 14.5), 3.67 (s, 3H), 1.70–1.55 (m, 2H), 1.51 (s, 3H), 1.25–1.10 (m, 4H), 1.04 (qn, 2H, J = 7.2), 1.00–0.90 (m, 2H), 0.85 (t, 3H, J = 7.3), 0.78 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.3, 152.7, 137.5, 134.8, 131.2, 128.8, 128.3, 127.4, 126.0, 119.15, 68.9, 53.3, 51.2, 32.2, 31.7, 29.3, 26.7, 22.6, 14.9, 14.1; HRMS (ESI) for C22H32NO5 [M+H]+ found 390.2288, calc. 390.2275. 
 
Methyl (E)-benzyl(2,2,3,3,7-pentamethyl-10-oxo-4,9,11-trioxa-3-silatetradeca-7,13-dien-8-yl)carbamate (3j) 
Representative Procedure G.  Prepared from vinyl iodide 4j (0.802 g, 1.64 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.93 mL, 3.28 mmol, 2.0 equiv), TBHP (5.5 M in decane; 596 µL, 3.28 mmol, 2.0 equiv) using MeLi (1.24 M in Et2O; 3.04 mL, 3.77 mmol, 2.3 equiv) and AllocCl (784 µL, 7.37 mmol, 4.5 equiv) to give the desired product as a pale yellow oil (677g, 1.46 mmol, 89%): 1H NMR (CDCl3, 500 MHz) δ 7.38–7.21 (m, 5H), 5.85 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.33 (dqt, 1H, J = 17.2, 1.2), 5.26 (dd, 1H, J = 10.5, 1.2), 4.67–4-52 (br m, 2H) 4.52 (d, 2H, J = 5.7), 3.76 (s, 3H) 2.00 (t, 2H, J = 7.2), 3.52–3.30 (br m, 2H), 2.07–1.91 (br m, 2H), 1.63 (s, 3H), 0.86 (s, 9H), –0.01 (s, 6H); 13C NMR (CDCl3, 125 MHz) δ 156.3, 152.5, 137.5, 136.3, 131.3, 128.8, 128.4, 127.5, 123.5, 119.4, 69.1, 60.9, 53.5, 51.7, 35.7, 26.0, 18.4, 15.7, –5.27; HRMS (ACPI) for C24H38NO6Si [M+H]+ found 464.2452, calc. 464.2463. 
 
Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-phenylprop-1-en-1-yl)(benzyl)carbamate (3k) 
Representative Procedure G.  Prepared from vinyl iodide 4k (1.036 g, 2.54 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 3.00 mL, 5.09 mmol, 2.0 equiv), TBHP (5.5 M in decane; 833 µL, 4.58 mmol, 1.8 equiv) using MeLi (1.2 M in Et2O; 4.45 mL, 5.34 mmol, 2.1 equiv) and AllocCl (1.22 mL, 11.45 mmol, 4.5 equiv) to give the desired product as a yellow oil (836 g, 2.11 mmol, 85%): 1H NMR (CDCl3, 500 MHz) δ 7.30–7.00 (m, 10 H), 5.91 (J = 17.3, 10.3, 5.4)5.38 (d, 1H, J = 17.3), 5.31 (d, 1H, J = 10.5), 4.70–4.50 (br signal, 1H), 4.57 (d, 2H, J = 5.4), 4.40–4.20 (br signal, 1H) 3.63 (s,3H), (2.01 (s, 3H); 13C NMR (CDCl3, 125 MHz) δ 155.9, 152.2, 138.7, 137.6, 137.3, 131.2, 128.4, 128.3, 127.5, 127.3, 127.2 124.9, 119.5, 69.2, 53.3, 52.5, 18.5; HRMS (APCI) for C22H24NO5 [M+H]+ found 382.1633, calc. 382.1649. 
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Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-ethylhex-1-en-1-yl)(benzyl)carbamate (3l) 
Representative Procedure G.  Prepared from vinyl iodide 4l (0.395 g, 0.984 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.16 mL, 1.97 mmol, 2.0 equiv), TBHP (5.5 M in decane; 358 µL, 1.97 mmol, 2.0 equiv) using MeLi (1.25 M in Et2O; 1.81 mL, 2.26 mmol, 2.1 equiv) and AllocCl (470 µL, 4.43 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.317 g, 0.844 mmol, 86%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 5H), 5.81 (ddt, 1H, J = 17.2, 10.4, 5.7), 5.28 (d, 1H, J = 17.2, 1.2), 5.20 (d, 1H, J = 10.4, 1.2), 4.67 (br d, 2H, J = 14.2), 4.48 (dt, 1H, J = 5.7, 1.2), 4.37 (br d, J = 14.2), 3.68 (s, 3H), 1.93 (q, 2H, J = 7.3), 1.70–1.40 (m, 2H), 1.25–0.94 (m, 4H), 0.86 (t, 3H, J = 7.3), 0.70 (t, 3H, J = 7.3); 13C NMR (CDCl3, 100 MHz) δ 153.1, 137.5, 134.5, 131.4, 131.2, 129.0, 128.4, 127.5, 119.3, 69.1, 53.4, 51.3, 29.3, 28.9, 23.0, 21.7, 14.0, 11.8, one of the C=O peaks not observed; HRMS (APCI) for C21H30NO5 [M+H]+ found 376.2104, calc. 376.2118. 
 
Methyl (E)-(1-(((allyloxy)carbonyl)oxy)-2-ethyloct-1-en-1-yl)(benzyl)carbamate (3m) 
Representative Procedure G.  Prepared from vinyl iodide 4m (0.352 g, 0.820 mmol, 1 equiv) using tBuLi (1.6 M in hexane; 1.02 mL, 1.64 mmol, 2.0 equiv), TBHP (5.5 M in decane; 268 µL, 1.48 mmol, 1.8 equiv) using MeLi (1.24 M in Et2O; 1.39 mL, 1.72 mmol, 2.1 equiv) and AllocCl (392 µL, 3.69 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.299 g, 0.75 mmol, 90%): 1H NMR (CDCl3, 400 MHz) δ 7.40–7.10 (m, 5H), 5.80 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.26 (d, 1H, J = 17.2), 5.19 (d, 1H, J = 10.4), 4.66 (br d, 2H, J = 14.5), 4.47 (d, 1H, J = 5.6), 4.36 (br d, J = 14.5), 3.67 (s, 3H), 1.92 (q, 2H, J = 7.2), 1.70–1.40 (m, 2H), 1.25–1.10 (m, 4H), 1.04 (qn, 2H, J = 7.2), 1.00–0.90 (m, 2H), 0.85 (t, 3H, J = 7.3), 0.78 (t, 3H, J = 7.2); 13C NMR (CDCl3, 100 MHz) δ 156.4, 153.0, 137.4, 134.4, 131.3, 131.1, 128.9, 128.3, 127.5, 119.2, 68.9, 53.3, 51.1, 31.7, 29.50, 29.45, 26.7, 22.6, 21.6, 14.1, 11.7; HRMS (ESI) for C23H34NO5 [M+H]+ found 404.2435, calc. 404.2435. 
 
Methyl (Z)-(1-(((allyloxy)carbonyl)oxy)-2-(3-phenylpropyl)oct-1-en-1-yl)(benzyl)carbamate (3n) 
Representative Procedure G.  Prepared from vinyl iodide 4o (0.868 g, 1.67 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.97 mL, 3.34 mmol, 2.0 equiv), TBHP (5.5 M in decane; 607 µL, 3.34 mmol, 2.0 equiv) using MeLi (1.2 M in Et2O; 3.20 mL, 3.84 mmol, 2.3 equiv) and AllocCl (888 µL, 8.35 mmol, 5.0 equiv) to give the desired product as a yellow oil (0.681 g, 1.38 mmol, 82%): 1H NMR (CDCl3, 500 MHz) δ 7.39–7.31 (m, 2H), 7.31–7.21 (m, 5H), 7.21–7.12 (m, 3H), 5.87 (ddt, 1H, J = 17.2, 10.4, 5.6), 5.34 (dqt, 1H, J = 17.2, 1.2), 5.28 (dd, 1H, J = 10.4, 1.2), 4.76 (br d, 2H, J = 14.6), 4.52 (dd, 1H, J = 5.6, 1.2), 4.41 (br d, J = 14.6), 3.75 (s, 3H), 2.62–2.46 (m, 2H), 2.07–1.94 (m, 2H), 1.75–1.57 (m, 4H), 1.24–1.15 (m, 4H), 1.13–1.05 (m, 2H), 1.03–0.97 (m, 2H), 0.86 (t, 3H, J = 7.2); 
13C NMR (CDCl3, 125 MHz) δ 156.4, 152.9, 142.2, 137.3, 135.0, 131.3, 129.4, 129.0, 128.5, 128.4, 127.5, 125.8, 119.3, 69.0, 53.4, 51.0, 35.6, 31.7, 30.4, 29.8, 29.7, 29.5, 28.8, 27.9, 26.8, 22.6, 14.2; HRMS (ESI) for C30H40NO5 [M+H]+ found 494.2918, calc. 494.2901. 
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(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3o) 
Representative Procedure G.  Prepared from vinyl iodide 4p (1.625 g, 5.03 mmol, 1 equiv) using tBuLi (1.56 M in hexane; 6.45 mL, 10.06 mmol, 2.0 equiv), TBHP (5.5 M in decane; 1.83 mL, 10.06 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 7.23 mL, 11.57 mmol, 2.3 equiv) and AllocCl (2.41 mL, 22.6 mmol, 4.5 equiv) to give the desired product as a yellow oil (1.188 g, 4.11 mmol, 79%): 1H NMR (CDCl3, 400 MHz) δ 5.87 (ddt, 1H, J = 17.2, 10.8, 5.7), 5.31 (d, 1H, J = 17.2, 1.3), 5.22 (d, 1H, J = 10.8, 1.3), 4.59 (dt, 2H, J = 5.7, 1.2), 4.31 (t, 2H, J = 7.7), 3.74 (d, 2H, J = 7.7), 2.10–1.95 (m, 4H), 1.36 (qn, 2H, J = 6.9), 1.25 (sx, 2H, J = 6.9), 1.01 (t, 3H, J = 7.6), 0.87 (t, 3H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 155.8, 153.3, 132.1, 131.7, 130.9, 119.2, 69.0, 62.5, 45.6, 29.3, 29.1, 22.6, 21.9, 13.8, 11.9; HRMS for C15H24NO5 [M+H]+ found 298.1623, calc. 298.1649. 
 
(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)oct-1-en-1-yl) carbonate (3p) 
Representative Procedure G.  Prepared from vinyl iodide 4q (0.416 g, 1.18 mmol, 1 equiv) using tBuLi (1.7 M in hexane; 1.39 mL, 2.37 mmol, 2.0 equiv), TBHP (5.5 M in decane; 431 µL, 2.37 mmol, 2.0 equiv) using MeLi (1.6 M in Et2O; 1.70 mL, 2.72 mmol, 2.3 equiv) and AllocCl (566 µL, 5.33 mmol, 4.5 equiv) to give the desired product as a yellow oil (0.327 g, 1.00 mmol, 85%): 1H NMR (CDCl3, 400 MHz) δ 5.93 (ddt, 1H, J = 17.2, 10.4, 5.8), 5.38 (d, 1H, J = 17.2, 1.2), 5.30 (d, 1H, J = 10.4, 1.2), 4.66 (d, 2H, J = 5.8), 4.38 (t, 2H, J = 7.7), 3.81 (d, 2H, J = 7.7), 2.20–2.00 (m, 4H), 1.50–1.40 (m, 2H), 1.40–1.20 (m, 6H), 1.01 (t, 3H, J = 7.6), 0.87 (t, 3H, J = 6.9); 13C NMR (CDCl3, 100 MHz) δ 155.9, 153.6, 132.6, 131.8, 131.1, 119.5, 69.3, 62.7, 45.9, 31.7, 29.6, 29.5, 27.4, 22.7, 22.2, 14.2, 12.1; HRMS for C17H28NO5 [M+H]+ found 326.1935, calc. 326.1962. 
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3.3 Decarboxylative Allylic Alkylation 
3.3.1 Ligand Synthesis 
 
 
 
Methyl 2-bromo-5-(trifluoromethyl)benzoate (S2) 
To an oven-dried round-bottom flask and magnetic stir bar was added 2-bromo-5-(trifluoromethyl)benzoic acid (S1)[12] (1.91 g, 7.10 mmol) followed by anhydrous DMF (20.0 mL).  The solution was stirred under nitrogen at room temperature.  Solid potassium carbonate (1.08 g, 7.81 mmol) was added in one portion followed by methyl iodide (0.53 mL, 8.52 mmol) dropwise by syringe.  The reaction was stirred at room temperature for 16h.  Afterward, the reaction mixture was poured into water (300 mL) and extracted with ethyl acetate (3 x 80 mL).  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate, filtered and concentrated in vacuo to afford the product (1.83 g, 91% yield), which was not purified further.  Characterization data matched literature values:[13] 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.59 –7.56 (m, 1H), 3.97 (s, 3H). 
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Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphoryl)-5-(trifluoromethyl)benzoate (S3) 
Procedure adapted from Stankevič and Włodarcyk.[14]  To an oven dried Schlenk tube equipped with a magnetic 
stir bar was added CuI (0.145 g, 0.761 mmol).  The tube was purged with nitrogen and (S)--phenylethylamine (0.100 mL, 0.760 mmol) was added with a micro-syringe followed by S2 (1.09 g, 3.8 mmol) dissolved in toluene (19.0 mL) with a syringe.  The reaction mixture was stirred under nitrogen for 5 minutes at room temperature.  Bis(4-(trifluoromethyl)phenyl)phosphine oxide[Error! Bookmark not defined.] (1.30 g, 3.84 mmol) was added to the reaction mixture in one portion and stirring continued for five minutes.  Potassium carbonate (1.05 g, 7.60 mmol) was added to the reaction mixture and the tube was sealed with a Teflon cap and electrical tape and heated to 110 °C behind a blast shield for 24 hours.  The mixture was cooled to room temperature and the mixture was filtered through a pad of celite, eluting with dichloromethane.  This mixture was concentrated in vacuo and purified by flash chromatography (30:70 to 35/65, EtOAc/hexanes) to provide the product as an amorphous white solid (1.61 g, 78% yield); 1H NMR (500 MHz, CDCl3) δ 8.27 – 8.22 (m, 1H), 7.95 – 7.87 (m, 2H), 7.84 – 7.73 (m, 8H), 3.59 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 165.7 (d, J = 2.5 Hz), 136.7 – 136.6 (m), 136.2 (d, J = 6.3 Hz), 135.8 (d, J = 10.4 Hz), 135.8 (m), 134.9 (qd, J = 34.2, 2.4 Hz), 134.2 (qd, J = 32.9, 3.0 Hz), 132.3 (d, J = 10.4 Hz), 128.5 (dq, J = 11.9, 3.6 Hz), 127.9 (dq, J = 7.2, 3.5 Hz), 125.7 (dq, J = 12.8, 3.7 Hz), 123.5 (q, J = 272.6 Hz), 123.0 (q, J = 273.1 Hz), 53.1; 19F NMR (282 MHz, CDCl3) δ -63.2, -63.4; 31P NMR (121 MHz, CDCl3) δ 28.7; IR (Neat Film, NaCl) 1737, 1440, 1324, 1269, 1131, 715 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C23H15F9O3P [M+H]+: 541.0610, found 541.0616. 
 
Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoate (S4) 
To an oven-dried Schlenk flask equipped with a magnetic stir bar was added S3 (0.650 g, 1.20 mmol) in toluene (17.5 mL).  The mixture was stirred under flow of nitrogen at room temperature.  Triethylamine (0.730 mL, 5.22 mmol) was added to the reaction mixture followed by trichlorosilane (0.510 mL, 5.04 mmol) with a syringe.  At this stage, the reaction mixture was heated to 110 °C behind a blast shield for 16 hours.  The reaction mixture was cooled to room temperature, diluted with ethyl acetate (40 mL), and quenched with a solution of saturated sodium bicarbonate (0.5 mL).  The mixture was filtered through celite and eluted with ethyl acetate followed by drying with sodium sulfate.  The mixture was filtered, concentrated in vacuo and purified by flash chromatography (2:98 to 4:96, EtOAc/hexanes) to provide the product as a slightly yellow oil that solidified at –20 °C and remained solid at room temperature (0.55 g, 87% yield).  The purified product slowly oxidizes in the time it takes to characterize; 
1H NMR (500 MHz, CDCl3) δ 8.38 (ddt, J = 3.6, 2.1, 0.7 Hz, 1H), 7.68 (dd, J = 8.3, 1.9 Hz, 1H), 7.64 – 7.59 (m, 4H), 7.36 (dddd, J = 7.3, 6.5, 1.7, 0.8 Hz, 4H), 7.02 (ddt, J = 8.1, 3.3, 0.7 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 165.9 (d, J = 2.4 Hz), 143.9 (d, J = 29.8 Hz), 141.4 (d, J = 13.7 Hz), 135.8 (d, J = 10.5 Hz), 134.9, 134.2 (d, J = 21.3 Hz), 131.5 (q, J = 32.6 Hz), 131.5 (q, J = 33.2 Hz), 128.9 (q, J = 3.5 Hz), 128.1 – 127.8 (m), 125.7 (dq, J = 7.5, 3.7 Hz), 124.0 (q, J = 272.4 Hz), 123.5 (q, J = 272.7 Hz), 53.0; 19F NMR (282 MHz, CDCl3) δ –62.9, –63.1; 31P NMR (121 MHz, CDCl3) δ –5.0; IR (Neat Film, NaCl) 1723, 1324, 1257, 1128, 832 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C23H15F9O2P [M+H]+: 525.0660, found 525.0646. 
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2-(Bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoic acid (S5) 
Compound S4 (0.550 g, 1.05 mmol) was charged into a round bottom flask equipped with a magnetic stir bar and was dissolved in THF (4.2 mL) at room temperature.  Water (4.2 mL) was added to this solution followed by lithium hydroxide monohydrate (0.882 g, 21.0 mmol).  The reaction mixture was sealed with a Teflon cap, stirred and heated to 70 °C for 12 hours.  The mixture was cooled to room temperature and diluted with ethyl acetate (50 mL).  This mixture was added to a 10% aqueous citric acid solution (50 mL) and this phase was extracted with ethyl acetate (2 x 50 mL).  The combined organic phases were washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo.  The crude material was purified by flash chromatography (3:97 to 5:95, MeOH:CH2Cl2) to provide the product as a white amorphous solid (0.492 g, 92% yield); 1H NMR (300 MHz, CD3OD) δ 8.39 (s, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.0 Hz, 4H), 7.43 (t, J = 7.6 Hz, 4H), 7.07 (dd, J = 8.1, 3.4 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ 168.5 (d, J = 5.1 Hz), 145.4 (d, J = 30.2 Hz), 143.9 (d, J = 14.6 Hz), 137.2 (d, J = 20.7 Hz), 136.0, 135.5 (d, J = 21.6 Hz), 132.1 (q, J = 32.3 Hz), 132.1 (q, J = 33.0 Hz), 129.5 (q, J = 3.4 Hz), 128.7 – 128.5 (m), 126.5 (dq, J = 7.4, 3.7 Hz), 125.5 (q, J = 271.5 Hz), 125.1 (q, J = 271.6 Hz); 19F NMR (282 MHz, cd3od) δ -64.3, -64.5; 31P NMR (121 MHz, MeOD) δ -4.9; IR (Neat Film, NaCl) 1698, 1324, 1127, 832 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C22H11F9O2P [M-H]-: 509.0358, found 509.0369. 
 
Electron deficient C2-symmetric ligand (L7) 
To an oven-dried flask equipped with a magnetic stir bar was added chiral diamine S6[15] (0.035 g, 0.149 mmol) and dichloromethane (2.6 mL) at room temperature under nitrogen.  Benzoic acid S5 (0.160 g, 0.313 mmol) was added to the reaction and an insoluble mixture was formed.  The reaction mixture was cooled to 0 °C and a single crystal of DMAP was added.  DCC (0.065 g, 0.313 mmol) was added in one portion and the mixture was slowly allowed to warm to room temperature overnight (12 hours).  At this time, the cloudy mixture was filtered through celite, eluting with dichloromethane, and concentrated.  The crude material was suspended in a small amount of diethylether and filtered once again through a pad of celite.  This mixture was concentrated and purified by flash chromatography (8:92 to 10:90, EtOAc:hexanes) to provide the product as a white amorphous solid (0.116 g, 64% yield); 1H NMR (500 MHz, CDCl3) δ 7.64 – 7.58 (m, 8H), 7.56 (d, J = 8.0 Hz, 4H), 7.40 (dd, J = 7.3, 1.3 Hz, 2H), 7.34 – 7.28 (m, 10H), 7.25 – 7.15 (m, 4H), 7.08 (dd, J = 8.1, 3.1 Hz, 2H), 5.82 (d, J = 7.7 Hz, 2H), 4.49 (d, J = 2.4 Hz, 2H), 4.15 – 4.08 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 167.2, 141.7 (d, J = 28.3 Hz), 141.1 (dd, J = 25.5, 14.6 Hz), 140.6 , 140.3 (d, J = 25.0 Hz), 138.5, 135.5, 133.9 (dd, J = 20.8, 7.0 Hz), 131.9 (q, J = 33.3 Hz), 131.5 (qd, J = 32.6, 1.3 Hz), 127.5 (q, J = 3.4 Hz), 127.4, 127.1, 125.9, 125.7 (dt, J = 6.9, 3.6 Hz), 125.3, 124.3 – 123.9 (m), 123.97 (qd, J = 272.3, 5.8 Hz), 123.3 (q, J = 272.8 Hz), 57.8, 48.9; 19F NMR (282 MHz, CDCl3) δ –62.9, –62.9, –63.1; 31P NMR (121 MHz, CDCl3) δ –10.70; IR (Neat Film, NaCl) 1659, 1509, 1397, 1325, 1172, 1130, 1061, 832 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C60H37F18N2O2P2 [M+H]+: 1221.2037, found 1221.2039; [α]25 –55.0 (c 3.17 CHCl3). 
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Methyl 2-(di-o-tolylphosphanyl)benzoate (S9) 
In a nitrogen filled glove box, an oven-dried round-bottom flask equipped with a magnetic stir bar was charged with di-(o-tolyl)phosphine (S7) (0.321 g, 1.50 mmol).  The flask was sealed with a cap equipped with a septa and electrical tape and removed from the glove box.  The flask was then charged with THF (8.0 mL) under positive nitrogen pressure.  This mixture was cooled to –78 °C in a dry ice/acetone bath. A freshly prepared solution of KHMDS (2.00 mL, 1.65 mmol, 0.825 M) was added to the mixture dropwise by syringe.  The reaction mixture was stirred at this temperature for 30 min and then warmed to room temperature.  Methyl-2-fluorobenzoate (S8) (0.13 mL, 1.0 mmol) was added dropwise and the mixture was stirred for 2.5 hours.  A precipitate formed and the reaction turned black in color.  The mixture was quenched and diluted with water (10 mL).  The aqueous phase was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were dried with sodium sulfate, filtered and evaporated in vacuo.  The crude material was purified by flash chromatography (5:95, EtOAc:hexanes) to provide the product as a white amorphous solid (0.238 g, 68% yield); 1H NMR (300 MHz, CDCl3) δ 8.10 (ddd, J = 7.2, 3.9, 1.8 Hz, 1H), 7.42 (pd, J = 7.4, 1.7 Hz, 2H), 7.33 – 7.21 (m, 4H), 7.08 (td, J = 7.0, 6.5, 2.3 Hz, 2H), 6.97 (ddt, J = 7.7, 3.6, 1.6 Hz, 1H), 6.75 (ddd, J = 7.5, 4.3, 1.2 Hz, 2H), 3.77 (s, 3H), 2.44 (d, J = 1.7 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 167.3 (d, J = 1.9 Hz), 142.6 (d, J = 27.7 Hz), 139.5 (d, J = 25.4 Hz), 136.1 (d, J = 11.4 Hz), 134.9 (d, J = 20.3 Hz), 134.5, 133.2, 132.2, 131.0 (d, J = 3.0 Hz), 130.2 (d, J = 4.8 Hz), 128.8, 128.4, 126.2, 52.2, 21.4 (d, J = 22.6 Hz); 31P NMR (121 MHz, CDCl3) δ –20.4; IR (Neat Film, NaCl) 3055, 1721, 1452, 1269, 1107, 749 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C22H22O2P [M+H]+: 349.1352, found 349.1362. 
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2-(Di-o-tolylphosphanyl)benzoic acid (S10) 
Compound S9 (0.238 g, 0.683 mmol) was charged into a round bottom flask equipped with a magnetic stir bar and was dissolved in THF (2.8 mL) at room temperature.  Water (2.8 mL) was added to this solution followed by lithium hydroxide monohydrate (0.574 g, 13.7 mmol).  The reaction mixture was sealed with a Teflon cap, stirred and heated to 70 °C for 12 hours.  The mixture was cooled to room temperature and diluted with ethyl acetate (30 mL).  This mixture was added to a 10% aqueous citric acid solution (50 mL) and this phase was extracted with ethyl acetate (2 x 30 mL).  The combined organic phases were washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo.  The crude material was purified by flash chromatography (40:60, EtOAc:hexanes) to provide the product as a white amorphous solid (0.205 g, 90% yield).  Characterization data matched literature values.[16]  1H-NMR (500 MHz, CDCl3) δ 8.14–8.20 (m, 1H), 7.38–7.45 (m, 2H), 7.18–7.27 (m, 4H), 7.05 (t, J = 7.5 Hz, 2H), 6.96–7.01 (m, 1H), 6.68–6.72 (m, 2H), 2.40 (s, 6H); HRMS (MM: ESI-APCI) m/z calc’d for C21H18O2P [M-H]-: 333.1044, found 333.1050. 
 
Sterically hindered C2-symmetric ligand (L8) 
To an oven-dried flask equipped with a magnetic stir bar was added S6[Error! Bookmark not defined.] (0.050 g, 0.212 mmol) and dichloromethane (3.0 mL) at room temperature under nitrogen.  Benzoic acid S10 (0.150 g, 0.450 mmol) was added to the reaction and an insoluble mixture was formed.  The reaction mixture was cooled to 0 °C and a single crystal of DMAP was added.  DCC (0.093 g, 0.45 mmol) was added all at once and the mixture was slowly allowed to warm to room temperature overnight (12 hours).  At this time, the cloudy mixture was filtered through celite, eluting with dichloromethane, and concentrated.  The crude material was suspended in a small amount of diethylether and filtered once again through a pad of celite.  This mixture was concentrated and purified by flash chromatography (20:80 to 40:60, Et2O:pentane) to provide the product as a white amorphous solid (0.136 g, 74% yield); 1H NMR (300 MHz, CDCl3) δ 7.55 – 7.48 (m, 2H), 7.39 – 7.20 (m, 14H), 7.15 – 7.06 (m, 4H), 7.04 – 6.93 (m, 6H), 6.88 (ddd, J = 7.5, 4.2, 1.3 Hz, 2H), 6.75 – 6.68 (m, 2H), 6.65 (dd, J = 7.6, 4.3 Hz, 2H), 5.74 (d, J = 7.1 Hz, 2H), 4.36 (s, 2H), 3.83 (d, J = 7.0 Hz, 2H), 2.35 (d, J = 4.6 Hz, 12H); 13C NMR (126 MHz, CDCl3) δ 169.1 (d, J = 1.8 Hz), 142.6 – 142.2 (m), 141.0, 138.7, 135.3 (d, J = 10.8 Hz), 134.9, 134.2 (d, J = 18.4 Hz), 132.9 (d, J = 62.2 Hz), 130.5 (dd, J = 14.7, 4.6 Hz), 130.4, 129.2, 128.9 (d, J = 10.1 Hz), 128.0 (d, J = 6.1 Hz), 126.7 (d, J = 11.0 Hz), 126.4 (d, J = 30.4 Hz), 125.9, 124.8, 57.9, 48.6, 21.5 (dd, J = 21.6, 9.6 Hz); 31P NMR (121 MHz, CDCl3) δ –26.5; IR (Neat Film, NaCl) 3054, 1658, 1501, 908, 748 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C58H51N2O2P2 [M+H]+: 869.3420, found 869.3433; [α]25 –84.1 (c 1.83, CHCl3). 
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3.3.2 Exploratory Allylic Alkylation Screen 
Initially, we ran a series of screens to determine the best combination of ligand and solvent that provided the highest %ee for the allylic alkylation.  The following procedure was followed to conduct these screens.  This procedure is similar to that previously used by the Stoltz group.[17] To separate enantiomers, the allylic alkylation products were derivitized using a cross metathesis with Grubbs-second generation catalyst and methyl acrylate.  This procedure is similar to that previously used by the Stoltz group.[18] 
General Screening Procedure (from Table S1 and Table S2):  
In a nitrogen-filled glove box, 38.0 mg Pd(dba)2 was taken up in 10 mL THF.  To each of 16 half-dram vials, 0.5 mL of this solution (1.90 mg Pd(dba)2, 1.65 mol, 0.100 equiv) was added.  The THF was then removed by evacuation using a Genevac centrifugal evaporator within the glove box.  To each of the vials was then added 500 L of the reaction solvent followed by a small stirring bar.  Stock solutions of ligand (0.0165 M) were made in each 
reaction solvent.  From these ligand stock solutions, 250 L (4.13 mol, 0.125 equiv) were added to the corresponding reaction vials.  The resulting catalyst solutions were stirred in the glove box for 30 minutes at the indicated reaction temperature.  Stock solutions of reaction substrate (0.132 M) were made in each reaction solvent.  
To the stirring catalyst solutions were added 250 L (33.0 mol, 1.00 equiv) of the corresponding substrate solution, resulting in a final reaction volume of 1.00 mL (0.033 M with respect to substrate).  The reactions were sealed with a Teflon-lined cap and stirred for the indicated reaction duration.  The reactions were then removed from the glove box, diluted with 1 mL hexanes and filtered through a silica plug, concentrated in vacuo, taken up in CDCl3 and analyzed by crude 1H NMR to determine conversion. 
The crude reaction mixtures in CDCl3 were concentrated in vacuo in half-dram vials and returned to the glove box.  To each half-dram vial was added 500 L of methyl acrylate solution in CH2Cl2 (0.66 M, 0.33 mmol, 10 equiv) was added, followed by a small stir bar.  The reactions were stirred for approximately 15 minutes.  To the resulting 
solutions were added 500 L each of a Grubb’s second-generation Ru catalyst solution in CH2Cl2 (0.004 M, 2 mol, 0.06 equiv).  The reactions were then stirred at 40 °C for 3 hours, removed from the glove box, filtered through a silica plug, concentrated in vacuo and analyzed by crude 1H NMR to determine conversion and chiral SFC to determine enantiomeric excess.  SFC conditions for each substrate can be found in a table at the end of the text portion of the SI. 
 
2.3.2.1  Characterization data for 5ab and 5c 
 
3-(2-Allyl-2-methylhexanoyl)oxazolidin-2-one (5ab) 
Prepared from 3a or 3b and L6 (Table S1, entries 6, 7, 13, 14): 
1H NMR (500 MHz, CDCl3) δ 5.72 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.10 – 5.01 (m, 2H), 4.42 – 4.34 (m, 2H), 4.09 – 3.98 (m, 2H), 2.92 – 2.84 (m, 1H), 2.36 (ddt, J = 14.1, 7.2, 1.2 Hz, 1H), 2.10 (ddd, J = 13.7, 11.9, 4.6 Hz, 1H), 1.67 (ddd, J = 13.6, 12.4, 4.3 Hz, 1H), 1.31 (s, 3H), 1.30 – 1.19 (m, 3H), 1.15 – 1.03 (m, 1H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.3, 152.4, 134.5, 117.8, 62.3, 49.0, 45.4, 41.0, 35.8, 27.0, 23.2, 22.5, 14.1; IR (Neat Film, NaCl) 2958, 2928, 1777, 1685, 1382, 1200 cm-1; HRMS (FAB+) m/z calc’d for C13H22NO3 [M+H]+: 240.1600, found 240.1601. 
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1-(2-Allyl-2-methylhexanoyl)indolin-2-one (5c) 
Prepared from 3c and L6 (Table S1, entry 16): 
1H NMR (500 MHz, CDCl3) δ 7.88 – 7.82 (m, 1H), 7.24 – 7.17 (m, 3H), 5.80 – 5.68 (m, 1H), 5.12 – 5.03 (m, 1H), 5.05 – 5.00 (m, 1H), 2.97 (dd, J = 14.1, 7.4 Hz, 1H), 2.48 (dd, J = 14.1, 7.3 Hz, 1H), 2.18 (td, J = 12.6, 11.4, 4.3 Hz, 1H), 1.78 (td, J = 14.1, 3.8 Hz, 1H), 1.43 (s, 3H), 1.35 – 1.23 (m, 3H), 1.23 – 1.11 (m, 1H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.3, 150.5, 143.0, 133.9, 129.4, 125.0, 124.6, 118.7, 116.1, 109.9, 50.5, 41.2, 36.1, 27.0, 23.3, 22.4, 14.1; IR (Neat Film, NaCl) 2958, 2932, 1795, 1479, 1299, 1027, 757 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C17H22NO3 [M+H]+: 288.1600, found 288.1603. 
 
3.3.2.2  Characterization data for 6ab and 6c. 
 
Methyl (E)-5-methyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6ab) 
Prepared from 3ab and L6 (Table S1, entries 6, 7, 13, 14): 
1H NMR (500 MHz, CDCl3) δ 6.85 (dt, J = 15.4, 7.7 Hz, 1H), 5.86 (dt, J = 15.5, 1.4 Hz, 1H), 4.40 (t, J = 8.0 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 3.71 (s, 3H), 3.01 (ddd, J = 14.5, 7.6, 1.5 Hz, 1H), 2.51 (ddd, J = 14.5, 7.9, 1.4 Hz, 1H), 2.01 (ddd, J = 13.8, 11.9, 4.8 Hz, 1H), 1.76 (ddd, J = 13.8, 12.1, 4.7 Hz, 1H), 1.34 (s, 3H), 1.31 – 1.24 (m, 2H), 1.24 – 1.07 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 176.7, 166.8, 152.5, 145.4, 123.9, 62.4, 51.6, 49.0, 45.4, 39.8, 35.8, 27.0, 23.2, 22.4, 14.1; IR (Neat Film, NaCl) 2931, 2957, 1778, 1723, 1688, 1274, 1197 cm-1; HRMS (FAB+) m/z calc’d for C15H24NO5 [M+H]+: 298.1654, found 298.1650. 
 
Methyl (E)-5-methyl-5-(2-oxo-2,3-dihydrobenzo[d]oxazole-3-carbonyl)non-2-enoate (6c) 
Prepared from 3c and L6 (Table S1, entry 16): 
1H NMR (500 MHz, CDCl3) δ 7.89 – 7.85 (m, 1H), 7.26 – 7.19 (m, 3H), 6.90 (dt, J = 15.4, 7.7 Hz, 1H), 5.90 (dt, J = 15.5, 1.4 Hz, 1H), 3.70 (s, 3H), 3.08 (ddd, J = 14.3, 7.5, 1.4 Hz, 1H), 2.66 (ddd, J = 14.3, 7.9, 1.4 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.94 – 1.84 (m, 1H), 1.46 (s, 3H), 1.36 – 1.14 (m, 4H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 176.5, 166.6, 150.5, 144.5, 143.0, 129.2, 125.2, 124.8, 124.4, 116.2, 110.0, 51.7, 50.3, 39.9, 36.0, 27.0, 23.1, 22.0, 14.0; IR (Neat Film, NaCl) 2256, 1796, 1722, 1479, 1272, cm-1; HRMS (FAB+) m/z calc’d for C19H24NO5 [M+H]+: 346.1654, found 346.1650. 
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3.3.3 Allylic Alkylation Substrate Library  
 
Representative Procedure H. (Compounds 5) 
Unless otherwise noted, the allylic alkylation reactions proceeded as follows: Outside of a glove box, an oven-dried 
2-dram vial equipped with a magnetic stir bar was charged with Pd(dba)2 (2.3 mg, 4.0 mol, 4 mol %).  A second oven-dried two-dram vial was charged with allylenolcarbonate 3d–3q (0.1 mmol).  Finally, a third oven-dried 2-
dram vial was charged with C-2 symmetric ligand L6 or L7 (7.0 mol).  These three uncapped vials were brought into a nitrogen-filled glove box through a small antechamber with 4 x 5 minute vacuum cycles with nitrogen back-filling.  To the vial containing compounds 3d–3q was added or THF (0.3 mL) unless otherwise noted.  To the vial containing C-2 symmetric ligand (L6 or L7) was added THF (0.3 ml) unless otherwise noted.  To the vial containing Pd(dba)2 and a magnetic stir bar was added the entirety of the ligand solution and the reaction was capped, cooled to 20 °C and stirred for 30 min to form the catalyst.  At this time, the entirety of the solution containing the substrate (3d–3q) were added to the catalyst mixture dropwise and the reactions were allowed to stir at 20 °C for 24h.  The reaction mixtures were removed from the glove box through the small antechamber and diluted with hexanes (1mL).  The mixture was filtered through a short plug of silica gel and eluted with ethyl acetate.  The crude material was concentrated and purified by preparative TLC (EtOAc:hexanes mixtures) to provide the products as clear to slightly yellow oils (53–88% yield).  Purified products were converted to the corresponding methyl acrylate species via cross metathesis for SFC analysis. 
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5d) 
Representative Procedure H.  Compound 5d was prepared from allylenolcarbonate 3d using General Procedure G (27.0 mg, 85% yield); 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H), 5.63 – 5.53 (m, 1H), 5.03 – 4.93 (m, 2H), 4.76 (s, 2H), 3.76 (s, 3H), 2.58 (ddt, J = 13.7, 7.2, 1.3 Hz, 1H), 2.27 (ddt, J = 13.7, 7.6, 1.2 Hz, 1H), 1.78 (ddd, J = 13.4, 12.3, 4.5 Hz, 1H), 1.52 (ddd, J = 13.3, 12.4, 4.5 Hz, 1H), 1.27 – 1.14 (m, 2H), 1.19 (s, 3H), 1.16 – 1.04 (m, 1H), 1.06 – 0.91 (m, 1H), 0.83 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.9, 155.6, 137.8, 134.6, 128.5, 128.3, 127.5, 117.8, 53.5, 50.6, 50.54, 44.1, 39.6, 26.8, 23.4, 22.5, 14.1; IR (Neat Film, NaCl) 2932, 2872, 1738, 1681, 1444, 1156, 998, 916 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C19H28NO3 [M+H]+: 318.2064, found 318.2064; [α]25 –2.36 (c 2.40, CHCl3, 92% ee). 
 
Ethyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5e) 
Representative Procedure H.  Compound 5e was prepared from allylenolcarbonate 3e using General Procedure G (20.5 mg, 62% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.12 (m, 5H), 5.56 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.02 – 4.87 (m, 2H), 4.72 (s, 2H), 4.15 (q, J = 7.1 Hz, 2H), 2.57 (ddd, J = 13.7, 7.1, 1.3 Hz, 1H), 2.25 (ddd, J = 13.7, 7.1, 1.3 Hz, 1H), 1.76 (td, J = 12.9, 4.5 Hz, 1H), 1.50 (td, J = 12.9, 4.5 Hz, 1H), 1.20 (t, J = 7.1 Hz, 3H), 1.20 – 1.13 (m, 2H), 1,17 (s, 3H), 1.12 – 1.02 (m, 1H), 1.02 – 0.92 (m, 1H), 0.79 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 183.1, 155.2, 138.0, 134.7, 128.4, 128.3, 127.4, 117.8, 63.0, 50.6, 50.5, 44.1, 39.5, 26.8, 23.4, 22.5, 14.3, 14.1; IR (Neat Film, NaCl) 2958, 2872, 1738, 1693, 1455, 1376, 1345, 1206, 1018 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H30NO3 [M+H]+: 332.2220, found 332.2219; [α]25 –3.19 (c 1.70, CHCl3, 94% ee).  
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tert-Butyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5f) 
Representative Procedure H.  Compound 5f was prepared from allylenolcarbonate 3f using General Procedure G (10.8 mg, 88% yield, 0.034mmol scale): 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.19 (m, 5H), 5.73 – 5.60 (m, 1H), 5.07 – 4.95 (m, 2H), 4.71 (s, 2H), 2.66 (ddt, J = 13.6, 7.2, 1.3 Hz, 1H), 2.32 (ddt, J = 13.5, 7.6, 1.2 Hz, 1H), 1.84 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.56 (ddd, J = 13.2, 12.4, 4.5 Hz, 1H), 1.36 (s, 9H), 1.28 – 1.20 (m, 2H), 1.26 (s, 3H), 1.20 – 1.12 (m, 1H), 1.07 (dddd, J = 15.0, 12.6, 7.3, 4.3 Hz, 1H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 183.3, 153.9, 138.5, 134.9, 128.4, 128.1, 127.3, 117.7, 82.7, 50.8, 50.3, 44.1, 39.5, 27.9, 26.9, 23.4, 22.5, 14.2; IR (Neat Film, NaCl) 2958, 2931, 2872, 1736, 1682, 1368, 1212, 987, 699 cm-1; HRMS (FAB+) m/z calc’d for C22H34NO3 [M+H]+: 360.2539, found 360.2527; [α]25 -2.89 (c 0.8, CHCl3, 90% ee). 
 
Benzyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5g) 
Representative Procedure H.  Compound 5g was prepared from allylenolcarbonate 3g using General Procedure G (21.0 mg, 53% yield); 1H NMR (500 MHz, CDCl3) δ 7.35 –7.31 (m, 3H), 7.28 – 7.20 (m, 7H), 5.61 – 5.51 (m, 1H), 5.15 (s, 2H), 4.97 – 4.93 (m, 1H), 4.93 – 4.91 (m, 1H), 4.78 (s, 2H), 2.58 (ddt, J = 13.6, 7.1, 1.2 Hz, 1H), 2.25 (ddt, J = 13.6, 7.7, 1.2 Hz, 1H), 1.75 (ddd, J = 13.3, 12.1, 4.4 Hz, 1H), 1.50 (ddd, J = 13.3, 12.4, 4.4 Hz, 1H), 1.18 (s, 3H), 1.16 – 1.12 (m, 2H), 1.10 – 1.02 (m, 1H), 1.02 – 0.91 (m, 1H), 0.80 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 183.1, 155.0, 137.9, 135.0, 134.6, 128.7, 128.7, 128.7, 128.5, 128.3, 127.5, 117.8, 68.7, 50.7, 50.6, 44.0, 39.4, 26.8, 23.3, 22.5, 14.1; IR (Neat Film, NaCl) 3067, 2957, 2932, 2872, 1732, 1696, 1456, 1386, 1347, 1192 cm-
1; HRMS (MM: ESI-APCI) m/z calc’d for C25H32NO3 [M+H]+: 394.2377, found 394.2376; [α]25 
 
–3.88 (c 1.91, 
CHCl3, 93% ee). 
 
Methyl (R)-(2-allyl-2-methylhexanoyl)(4-chlorophenyl)carbamate (5h) 
Representative Procedure H.  Compound 5h was prepared from allylenolcarbonate 3h using General Procedure G (20.7 mg, 62% yield); 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.33 (m, 2H), 7.14 – 7.10 (m, 2H), 5.77 – 5.66 (m, 1H), 5.09 – 5.00 (m, 2H), 3.75 (s, 3H), 2.54 (ddt, J = 13.8, 7.2, 1.3 Hz, 1H), 2.28 (ddt, J = 13.8, 7.5, 1.2 Hz, 1H), 1.76 – 1.65 (m, 1H), 1.55 – 1.47 (m, 1H), 1.29 – 1.20 (m, 4H), 1.19 (s, 3H), 0.86 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.3, 154.8, 137.1, 134.0, 133.9, 129.5, 129.3, 118.5, 53.8, 51.0, 43.4, 39.1, 26.6, 23.3, 22.9, 14.1; IR (Neat Film, NaCl) 2957, 2933, 1742, 1731, 1491, 1439, 1245, 1091 cm-1; HRMS (FAB+) m/z calc’d for C18H25NO3Cl [M+H]+: 338.1523, found 338.1531; [α]25 2.64 (c 1.9, CHCl3, 90% ee). 
  
S30  
 
 
Methyl (R)-(2-allyl-2-methyloctanoyl)(benzyl)carbamate (5i) 
Representative Procedure H.  Compound 5i was prepared from allylenolcarbonate 3i using General Procedure G (24.0 mg, 69% yield); 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 3H), 7.26 – 7.22 (m, 2H), 5.58 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.02 – 4.94 (m, 2H), 4.76 (s, 2H), 3.76 (s, 3H), 2.58 (ddt, J = 13.7, 7.0, 1.2 Hz, 1H), 2.27 (ddt, J = 13.6, 7.6, 1.2 Hz, 1H), 1.77 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.51 (ddd, J = 13.3, 12.0, 4.4 Hz, 1H), 1.19 (s, 3H), 1.28 – 1.14 (m, 6H), 1.16 – 1.06 (m, 1H), 1.05 – 0.95 (m, 1H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.88, 155.63, 137.81, 134.58, 128.45, 128.30, 127.49, 117.79, 53.54, 50.60, 50.57, 44.12, 39.90, 31.79, 29.97, 24.52, 22.73, 22.45, 14.22; IR (Neat Film, NaCl) 3067, 2950, 2930, 2858, 1738, 1694, 1455, 1445, 1351, 1208, 1000 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H32NO3 [M+H]+: 346.2377, found 346.2375; [α]25 
 
–2.14 (c 
2.18, CHCl3, 94% ee). 
 
Methyl (S)-benzyl(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enoyl)carbamate (5j) 
Representative Procedure H.  Compound 5j was prepared from allylenolcarbonate 3j using General Procedure G (32.1 mg, 76% yield); 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.18 (m, 5H), 5.52 (ddt, J = 17.2, 10.1, 7.3 Hz, 1H), 4.99 – 4.90 (m, 2H), 4.74 (s, 2H), 3.73 (s, 3H), 3.54 – 3.44 (m, 2H), 2.58 (dd, J = 13.6, 7.1 Hz, 1H), 2.27 (dd, J = 13.6, 7.5 Hz, 1H), 2.11 – 2.03 (m, 1H), 1.84 – 1.76 (m, 1H), 1.20 (s, 3H), 0.83 (d, J = 0.7 Hz, 9H), -0.03 (d, J = 1.8 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 182.1, 155.5, 137.8, 134.3, 128.5, 128.2, 127.5, 118.1, 59.9, 53.6, 50.6, 49.2, 44.5, 41.9, 26.1, 22.7, 18.4, –5.2, –5.2;  IR (Neat Film, NaCl) 2955, 2929, 2857, 1741, 1686, 1444, 1351, 1207, 1095, 837 cm-1; HRMS (FAB+) m/z calc’d for C23H38NO3 [M+H]+: 420.2570, found 420.2541; [α]25 
 
– 6.23 
(c 2.91, CHCl3, 94% ee). 
 
Methyl (S)-benzyl(2-methyl-2-phenylpent-4-enoyl)carbamate (5k) 
Representative Procedure H.  Compound 5k was prepared from allylenolcarbonate 3k using General Procedure G (26.0 mg, 77% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.30 (m, 4H), 7.30 – 7.23 (m, 3H), 7.20 – 7.15 (m, 1H), 7.06 – 7.01 (m, 2H), 5.34 (dddd, J = 16.8, 10.3, 8.1, 6.5 Hz, 1H), 4.95 (ddt, J = 8.7, 2.2, 1.2 Hz, 1H), 4.93 (h, J = 1.2 Hz, 1H), 4.88 (s, 2H), 3.22 (s, 3H), 2.90 (ddt, J = 13.7, 8.2, 1.0 Hz, 1H), 2.55 (ddt, J = 13.6, 6.6, 1.4 Hz, 1H), 1.63 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 179.7, 154.5, 143.7, 137.5, 134.3, 128.6, 128.5, 128.1, 127.6, 126.2, 125.9, 118.5, 54.0, 53.3, 50.1, 47.0, 23.8; IR (Neat Film, NaCl) 3064, 3007, 2954, 1755, 1674 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H23NO3 [M+H]+: 338.1751, found 338.1754; [α]25 
 
+ 71.01 (c 2.36, CHCl3, 76% ee). 
  
S31  
 
 
Methyl (R)-(2-allyl-2-ethylhexanoyl)(benzyl)carbamate (5l) 
Representative Procedure H.  Compound 5l was prepared from allylenolcarbonate 3l using General Procedure G (8.6 mg, 76% yield, 0.034 mmol scale).  Note: this reaction was run in EtOAc and not THF; 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H), 5.62 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.07 – 4.97 (m, 2H), 4.78 (s, 2H), 3.75 (s, 3H), 2.53 – 2.39 (m, 2H), 1.82 – 1.55 (m, 4H), 1.28 – 1.18 (m, 2H), 1.15 – 1.00 (m, 2H), 0.85 (t, J = 7.3 Hz, 3H), 0.76 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.7, 155.6, 137.9, 134.7, 128.5, 128.3, 127.5, 117.7, 54.0, 53.6, 50.8, 39.1, 35.0, 28.1, 26.7, 23.4, 14.1, 9.0; IR (Neat Film, NaCl) 2958, 2933, 2873, 1741, 1732, 1682, 1443, 1350, 1206, 699 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H29NO3 [M+H]+: 332.2220, found 332.2216; [α]25 +0.64 (c 0.7, CHCl3, 82% ee). 
 
Methyl (R)-(2-allyl-2-ethyloctanoyl)(benzyl)carbamate (5m) 
Representative Procedure H.  Compound 5m was prepared from allylenolcarbonate 3m using General Procedure G (24.0 mg, 64% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.17 (m, 5H), 5.62 (ddt, J = 17.3, 10.1, 7.3 Hz, 1H), 5.09 – 4.95 (m, 2H), 4.78 (s, 2H), 3.75 (s, 3H), 2.51 – 2.40 (m, 2H), 1.83 – 1.73 (m, 1H), 1.73 – 1.64 (m, 2H), 1.64 – 1.56 (m, 1H), 1.31 – 1.17 (m, 6H), 1.17 – 1.02 (m, 2H), 0.87 (t, J = 7.0 Hz, 3H), 0.76 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.7, 155.6, 137.9, 134.7, 128.5, 128.3, 127.5, 117.7, 54.0, 53.6, 50.8, 39.1, 35.3, 31.8, 30.0, 28.1, 24.4, 22.8, 14.2, 9.0; IR (Neat Film, NaCl)2956, 2872, 1739, 1685, 1443, 1350, 1206, 1183, 998 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C22H34NO3 [M+H]+: 360.2533, found 360.2530; [α]25 +1.25 (c 1.90, CHCl3, 93% ee).
  
 
 
Methyl (S)-(2-allyl-2-(3-phenylpropyl)octanoyl)(benzyl)carbamate (5n) 
Representative Procedure H.  Compound 5n was prepared from allylenolcarbonate 3n using General Procedure G (22.4 mg, 56% yield, 0.089 mmol scale); 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.09 (m, 10H), 5.61 – 5.52 (m, 1H), 5.01 – 4.98 (m, 1H), 4.97 –4.96 (m, 1H), 4.76 (s, 2H), 3.67 (s, 3H), 2.53 (t, J = 7.5 Hz, 2H), 2.43 (dq, J = 7.4, 1.3 Hz, 2H), 1.79 – 1.37 (m, 6H), 1.29 – 1.13 (m, 6H), 1.13 – 0.96 (m, 2H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.5, 155.5, 142.4, 137.8, 134.6, 128.6, 128.4, 128.4, 128.3, 127.5, 125.8, 117.8, 53.6, 53.5, 50.8, 39.6, 36.5, 35.7, 35.1, 31.8, 30.0, 26.3, 24.3, 22.7, 14.2; IR (Neat Film, NaCl) 2954, 2930, 1738, 1682, 1444, 1350, 1205, 1176, 699 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C29H40NO3 [M+H]+: 450.3003, found 450.2995; [α]25 –0.11 (c 2.0, CHCl3, 76% ee). 
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(R)-3-(2-Allyl-2-ethylhexanoyl)oxazolidin-2-one (5o) 
Representative Procedure H.  Compound 5o was prepared from allylenolcarbonate 3o using General Procedure G (16.3 mg, 67% yield); 1H NMR (500 MHz, CDCl3) δ 5.69 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.11 – 5.01 (m, 2H), 4.38 (dd, J = 8.4, 7.6 Hz, 2H), 4.04 (dd, J = 8.5, 7.6 Hz, 2H), 2.68 – 2.54 (m, 2H), 2.05 – 1.76 (m, 4H), 1.33 – 1.23 (m, 2H), 1.21 – 1.04 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H), 0.80 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.5, 152.4, 134.5, 117.9, 62.3, 52.7, 45.6, 36.6, 31.8, 26.6, 25.1, 23.3, 14.2, 8.8; IR (Neat Film, NaCl) 3076, 2960, 2931, 2874, 1778, 1682, 1468, 1384, 1202 cm-1; HRMS (FAB+) m/z calc’d for C14H24NO3 [M+H]+: 254.1756, found 254.1756; [α]25 
 
0.02 (c 1.45, CHCl3, 69% ee). 
 
(R)-3-(2-Allyl-2-ethyloctanoyl)oxazolidin-2-one (5p) 
Representative Procedure H.  Compound 5p was prepared from allylenolcarbonate 3p using General Procedure G (20.1 mg, 72% yield); 1H NMR (500 MHz, CDCl3) δ 5.77 – 5.58 (m, 1H), 5.14 – 4.96 (m, 2H), 4.38 (t, J = 8.0 Hz, 2H), 4.04 (t, J = 8.0 Hz, 2H), 2.70 – 2.48 (m, 2H), 2.05 – 1.73 (m, 4H), 1.33 – 1.05 (m, 8H), 0.87 (t, J = 6.7 Hz, 3H), 0.79 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 177.5, 152.4, 134.5, 117.9, 62.3, 52.8, 45.6, 36.6, 32.1, 31.8, 29.9, 25.1, 24.4, 22.8, 14.2, 8.8; IR (Neat Film, NaCl) 2958, 2926, 1779, 1682, 1467, 1383, 1228, 1194, 1107, 914 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C16H28NO3 [M+H]+: 282.2069, found 282.2078; [α]25 0.21 (c 1.67, CHCl3, 73% ee).
 
 
 
3.3.4  Cross Metathesis Procedure 
 
Representative Procedure I. (Compounds 6) 
Unless otherwise noted, the cross metathesis procedure was executed as follows: The allylic alkylation substrates were loaded into a 2-dram vial equipped with a magnetic stirring bar and brought into a glove box.  A solution of methacrylate (0.06M, 10 equiv.) in dichloromethane was added and the vial was capped with a Teflon lined screw-cap.  The reaction mixture was stirred for 30 minutes.  A solution of Grubbs generation II catalyst (6.6 mM, 5 mol %) in dichloromethane was added to the reaction.  The mixture was sealed the cap and heated to 40 °C with stirring.  After 3 hours, the reaction mixture was cooled to room temperature and removed from the glovebox.  The reaction mixture was filtered through a silica plug, eluting with diethyl ether, and concentrated.  The crude material was purified by preparative TLC (EtOAc/hexanes mobile phase) to afford the product, which was analyzed by SFC to determine the % ee of the allylic alkylation.  
  
S33  
 
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6d) 
Representative Procedure I.  Compound 6d was prepared using General Procedure H with 5d (26.9 mg, 85 mol) to afford a clear oil (25.5 mg, 80% yield): 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.19 (m, 5H), 6.83 (dt, J = 15.5, 7.7 Hz, 1H), 5.81 (dt, J = 15.5, 1.4 Hz, 1H), 4.77 (s, 2H), 3.76 (s, 3H), 3.71 (s, 3H), 2.76 (ddd, J = 14.0, 7.6, 1.5 Hz, 1H), 2.44 (ddd, J = 14.0, 7.9, 1.4 Hz, 1H), 1.77 (ddd, J = 13.4, 12.2, 4.4 Hz, 1H), 1.55 (ddd, J = 13.4, 12.4, 4.6 Hz, 1H), 1.23 (s, 3H), 1.22 – 1.15 (m, 2H), 1.12 – 1.01 (m, 1H), 0.96 (ttd, J = 11.9, 7.4, 4.4 Hz, 1H), 0.81 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.0, 166.7, 155.5, 145.5, 137.6, 128.5, 128.2, 127.6, 123.8, 53.7, 51.6, 50.6, 50.6, 42.3, 39.7, 26.8, 23.3, 22.4, 14.1; IR (Neat Film, NaCl) 2957, 2872, 1726, 1686, 1439, 1350, 1272, 1195, 998 cm-1; HRMS (ESI) m/z calc’d for C21H33N2O5 [M+NH4]+: 393.2384, found 393.2376; [α]25 +12.17 (c 2.3, CHCl3, 92% ee). 
 
Methyl (R,E)-5-(benzyl(ethoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6e) 
Representative Procedure I.  Compound 6e was prepared using General Procedure H with 5e (17.4 mg, 53 mol) to afford a clear oil (17.4 mg, 85% yield): 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.19 (m, 5H), 6.84 (dt, J = 15.5, 7.7 Hz, 1H), 5.82 (dt, J = 15.5, 1.4 Hz, 1H), 4.77 (s, 2H), 4.25 – 4.12 (m, 2H), 3.71 (s, 3H), 2.78 (ddd, J = 13.9, 7.5, 1.5 Hz, 1H), 2.46 (ddd, J = 13.9, 7.9, 1.4 Hz, 1H), 1.80 (ddd, J = 13.4, 12.3, 4.4 Hz, 1H), 1.63 – 1.52 (m, 1H), 1.25 (s, 3H), 1.24 (t, J = 9.1, 3H), 1.23 – 1.16 (m, 2H), 1.14 – 1.03 (m, 1H), 0.98 (ttd, J = 12.4, 7.5, 4.4 Hz, 1H), 0.82 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.1, 166.8, 155.1, 145.6, 137.8, 128.5, 128.2, 127.5, 123.8, 63.1, 51.6, 50.6, 50.5, 42.2, 39.6, 26.8, 23.3, 22.5, 14.3, 14.1; IR (Neat Film, NaCl) 1956, 2873, 1727, 1688, 1436, 1376, 1345, 1272, 1193, 1019, 986 cm-1; HRMS (ESI) m/z calc’d for C22H35N2O5 [M+NH4]+: 407.2540, found 407.2538; [α]25 +9.70 (c 1.5, CHCl3, 94% ee). 
 
Methyl (R,E)-5-(benzyl(tert-butoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6f) 
Representative Procedure I.  Compound 6f was prepared using General Procedure H with 5f (9.3 mg, 26 mol) to afford a clear oil (8.5 mg, 79% yield): 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.17 (m, 5H), 6.88 (dt, J = 15.5, 7.7 Hz, 1H), 5.84 (dt, J = 15.5, 1.4 Hz, 1H), 4.71 (s, 2H), 3.72 (s, 3H), 2.83 (ddd, J = 13.9, 7.5, 1.5 Hz, 1H), 2.50 (ddd, J = 13.9, 7.9, 1.4 Hz, 1H), 1.84 (ddd, J = 13.4, 12.1, 4.4 Hz, 1H), 1.59 (ddd, J = 13.4, 12.3, 4.5 Hz, 1H), 1.35 (s, 9H), 1.29 (s, 3H), 1.27 – 1.19 (m, 2H), 1.13 (dddd, J = 17.0, 7.8, 6.6, 4.6 Hz, 1H), 1.04 (tdd, J = 12.4, 8.3, 4.5 Hz, 1H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.3, 166.9, 153.9, 145.9, 138.3, 128.4, 128.0, 127.3, 123.7, 83.0, 51.6, 50.8, 50.3, 42.4, 39.6, 27.9, 26.9, 23.4, 22.5, 14.2; IR (Neat Film, NaCl) 2957, 2933, 1728, 1682, 1370, 1272, 1150, 987, 699 cm-1; HRMS (FAB+) m/z calc’d for C24H36NO5 [M+H]+: 418.2593, found 418.2593; [α]25 +10.60 (c 0.85, CHCl3, 90% ee). 
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Methyl (R,E)-5-(benzyl((benzyloxy)carbonyl)carbamoyl)-5-methylnon-2-enoate (6g) 
Representative Procedure I.  Compound 6g was prepared using General Procedure H with 5g (20.9 mg, 53 mol) to afford a clear oil (18.2 mg, 76% yield): 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (m, 3H), 7.29 – 7.20 (m, 7H), 6.81 (dt, J = 15.4, 7.7 Hz, 1H), 5.75 (dd, J = 15.5, 1.4 Hz, 1H), 5.15 (s, 2H), 4.79 (s, 2H), 3.71 (s, 3H), 2.73 (ddd, J = 14.0, 7.6, 1.4 Hz, 1H), 2.43 (ddd, J = 13.9, 7.9, 1.5 Hz, 1H), 1.76 (ddd, J = 13.5, 12.2, 4.5 Hz, 1H), 1.61 – 1.48 (m, 1H), 1.22 (s, 3H), 1.14 (p, J = 7.2 Hz, 2H), 1.10 – 0.99 (m, 1H), 0.94 (ttd, J = 12.3, 7.4, 4.3 Hz, 1H), 0.79 (t, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.2, 166.8, 154.9, 145.5, 137.7, 134.9, 128.8, 128.8, 128.7, 128.5, 128.2, 127.5, 123.8, 68.9, 51.6, 50.6, 50.5, 42.1, 39.5, 26.8, 23.2, 22.5, 14.1; IR (Neat Film, NaCl) 2955, 1725, 1688, 1386, 1346, 1272, 1192, 990, 698 cm-1; HRMS (ESI) m/z calc’d for C27H37N2O5 [M+NH4]+: 469.2697, found 469.2693; [α]25 +5.94 (c 1.7, CHCl3, 93% ee). 
 
Methyl (R,E)-5-((4-chlorophenyl)(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6h) 
Representative Procedure I.  Compound 6h was prepared using General Procedure H with 5h (19.8 mg, 59 mol) to afford a clear oil (19.7 mg, 80% yield): 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.31 (m, 2H), 7.13 – 7.05 (m, 2H), 6.88 (dt, J = 15.4, 7.7 Hz, 1H), 5.83 (dt, J = 15.3, 1.3 Hz, 1H), 3.74 (s, 3H), 3.73 (s, 3H), 2.73 (ddd, J = 14.3, 7.6, 1.5 Hz, 1H), 2.44 (ddd, J = 14.1, 7.8, 1.4 Hz, 1H), 1.79 – 1.67 (m, 1H), 1.61 – 1.52 (m, 1H), 1.30 – 1.14 (m, 4H), 1.24 (s, 3H), 0.86 (t, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 181.7, 166.7, 154.7, 144.8, 136.9, 134.1, 129.5, 129.3, 124.2, 54.0, 51.7, 51.2, 41.8, 39.4, 26.6, 23.2, 22.9, 14.1; IR (Neat Film, NaCl) 2956, 2873, 1728, 1658, 1492, 1439, 1272, 1247, 1198, 1092 cm-1; HRMS (FAB+) m/z calc’d for C20H26NClO5 [M+H-H2]+: 395.1499, found 395.1476; [α]25 +7.94 (c 1.8, CHCl3, 90% ee). 
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylundec-2-enoate (6i) 
Representative Procedure I.  Compound 6i was prepared using General Procedure H with 5i (17.3 mg, 51 mol) to afford a clear oil (17.2 mg, 84% yield): 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.19 (m, 5H), 6.83 (dt, J = 15.5, 7.7 Hz, 1H), 5.81 (dt, J = 15.5, 1.4 Hz, 1H), 4.77 (s, 2H), 3.76 (s, 3H), 3.71 (s, 3H), 2.75 (ddd, J = 14.0, 7.5, 1.4 Hz, 1H), 2.45 (ddd, J = 13.9, 8.0, 1.4 Hz, 1H), 1.77 (ddd, J = 13.4, 12.1, 4.4 Hz, 1H), 1.61 – 1.46 (m, 1H), 1.30 – 1.13 (m, 6H), 1.23 (s, 3H), 1.13 – 1.03 (m, 1H), 1.02 – 0.91 (m, 1H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 182.0, 166.8, 155.5, 145.5, 137.6, 128.5, 128.2, 127.6, 123.8, 53.7, 51.6, 50.6, 50.6, 42.3, 40.0, 31.7, 29.9, 24.5, 22.7, 22.4, 14.2; IR (Neat Film, NaCl) 2954, 2930, 2858, 1728, 1688, 1441, 1350, 1272, 1779, 998 cm-1; HRMS (ESI) m/z calc’d for C23H37N2O5 [M+NH4]+: 421.2697, found 421.2688; [α]25 +10.91 (c 1.6, CHCl3, 94% ee). 
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Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-7-((tert-butyldimethylsilyl)oxy)-5-methylhept-2-enoate (6j) 
Representative Procedure I.  Compound 6j was prepared using General Procedure H with 5j (31.7 mg, 76 mol) to afford a clear oil (28.5 mg, 79% yield): 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.17 (m, 5H), 6.79 (dq, J = 15.4, 7.8 Hz, 1H), 5.77 (dt, J = 15.5, 1.4 Hz, 1H), 4.75 (s, 2H), 3.72 (s, 3H), 3.67 (s, 3H), 3.54 – 3.44 (m, 2H), 2.78 (ddd, J = 14.0, 7.6, 1.5 Hz, 1H), 2.47 (ddd, J = 14.0, 7.9, 1.5 Hz, 1H), 2.06 (ddd, J = 13.9, 7.8, 6.2 Hz, 1H), 1.86 (ddd, J = 13.9, 7.9, 6.3 Hz, 1H), 1.24 (s, 3H), 0.82 (s, 9H), -0.03 (s, 3H), -0.03 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 181.2, 166.7, 155.4, 145.3, 137.6, 128.6, 128.1, 127.6, 124.0, 59.8, 53.7, 51.6, 50.6, 49.3, 42.6, 41.8, 26.1, 22.7, 18.4, -5.2, -5.3; IR (Neat Film, NaCl) 2955, 2857, 1728, 1688, 1440, 1351, 1256, 1195, 1094, 994 cm-1; HRMS (FAB+) m/z calc’d for C25H40NO6Si [M+H]+: 478.2625, found 478.2646; [α]25 +2.20 (c 2.6, CHCl3, 94% ee). 
 
Methyl (S,E)-6-(benzyl(methoxycarbonyl)amino)-5-methyl-6-oxo-5-phenylhex-2-enoate (6k) 
Representative Procedure I.  Compound 6k was prepared using General Procedure H with 4k (26.0 mg, 77 mol) to afford a clear oil (23.9 mg, 78% yield): 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 4H), 7.30 – 7.23 (m, 3H), 7.22 – 7.13 (m, 1H), 7.05 – 6.97 (m, 2H), 6.57 (ddd, J = 15.4, 8.3, 6.9 Hz, 1H), 5.71 (dt, J = 15.5, 1.4 Hz, 1H), 4.89 (s, 2H), 3.67 (s, 3H), 3.22 (s, 3H), 3.01 (ddd, J = 13.9, 8.4, 1.2 Hz, 1H), 2.67 (ddd, J = 13.9, 6.9, 1.6 Hz, 1H), 1.68 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 179.0, 166.6, 154.3, 145.1, 142.7, 137.4, 128.5, 128.5, 128.3, 127.7, 126.6, 125.8, 124.3, 54.1, 53.4, 51.5, 50.1, 45.9, 23.4; IR (Neat Film, NaCl) 2953, 1725, 1674, 1496, 1441, 1351, 1315, 1274, 1203, 1004, 700 cm-1; HRMS (ESI) m/z calc’d for C23H29N2O5 [M+NH4]+: 413.2071, found 413.2065; [α]25 +67.74 (c 2.2, CHCl3, 76% ee). 
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylnon-2-enoate (6l) 
Representative Procedure I.  Compound 6l was prepared using General Procedure H with 5l (7.3 mg, 22 mol) to afford a clear oil (7.3 mg, 85% yield): 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.16 (m, 5H), 6.83 (dt, J = 15.4, 7.7 Hz, 1H), 5.84 (dt, J = 15.5, 1.4 Hz, 1H), 4.80 (s, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 2.62 (qdd, J = 14.4, 7.7, 1.5 Hz, 2H), 1.84 (dq, J = 14.8, 7.4 Hz, 1H), 1.75 (ddd, J = 13.8, 12.2, 4.7 Hz, 1H), 1.66 (dt, J = 14.3, 7.4 Hz, 1H), 1.59 (ddd, J = 13.8, 12.2, 4.7 Hz, 1H), 1.22 (p, J = 7.2 Hz, 2H), 1.15 – 0.97 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H), 0.76 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 180.8, 166.8, 155.5, 145.8, 137.7, 128.5, 128.2, 127.6, 123.6, 54.2, 53.7, 51.6, 50.8, 37.6, 35.2, 28.3, 26.7, 23.3, 14.1, 9.0; IR (Neat Film, NaCl) 2957, 2874, 1727, 1682, 1442, 1351, 1190, 700 cm-1; HRMS (ESI) m/z calc’d for C22H35N2O5 [M+NH4]+: 407.2540, found 407.2537; [α]25 +1.32 (c 0.66, CHCl3, 82% ee). 
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Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylundec-2-enoate (6m) 
Representative Procedure I.  Compound 6m was prepared using General Procedure H with 5m (19.0 mg, 53 mol) to afford a clear oil (18.7 mg, 85% yield): 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.14 (m, 5H), 6.83 (dt, J = 15.4, 7.7 Hz, 1H), 5.83 (dd, J = 15.5, 1.6 Hz, 1H), 4.79 (s, 2H), 3.75 (s, 3H), 3.72 (s, 3H), 2.62 (qdd, J = 14.6, 7.7, 1.5 Hz, 2H), 1.84 (dq, J = 14.8, 7.4 Hz, 1H), 1.78 – 1.70 (m, 1H), 1.69 – 1.54 (m, 2H), 1.30 – 1.15 (m, 6H), 1.15 – 0.97 (m, 2H), 0.86 (t, J = 7.0 Hz, 3H), 0.75 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 180.8, 166.8, 155.5, 145.8, 137.7, 128.5, 128.2, 127.5, 123.6, 54.2, 53.7, 51.6, 50.7, 37.6, 35.5, 31.7, 29.9, 28.3, 24.5, 22.7, 14.2, 9.0; IR (Neat Film, NaCl) 2955, 1727, 1683, 1441, 1351, 1176 cm-1; HRMS (ESI) m/z calc’d for C25H39N2O5 [M+NH4]+: 435.2853, found 435.2853; [α]25 +2.25 (c 1.7, CHCl3, 93% ee). 
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-(3-phenylpropyl)undec-2-enoate (6n) 
Representative Procedure I.  Compound 6n was prepared using General Procedure H with 5n (21.6 mg, 48 mol) to afford a clear oil (19.8 mg, 84% yield): 1H NMR (500 MHz, CDCl3) δ 7.30 – 7.14 (m, 8H), 7.13 – 7.07 (m, 2H), 6.79 (dt, J = 15.4, 7.6 Hz, 1H), 5.79 (dt, J = 15.4, 1.3 Hz, 1H), 4.78 (s, 2H), 3.72 (s, 3H), 3.67 (s, 3H), 2.60 (dt, J = 7.7, 1.3 Hz, 2H), 2.53 (t, J = 7.4 Hz, 2H), 1.84 – 1.68 (m, 2H), 1.65 – 1.51 (m, 2H), 1.51 – 1.35 (m, 2H), 1.29 – 1.13 (m, 6H), 1.12 – 0.93 (m, 2H), 0.86 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 180.6, 166.7, 155.4, 145.6, 142.1, 137.6, 128.5, 128.5, 128.4, 128.2, 127.6, 125.9, 123.7, 53.8, 53.7, 51.6, 50.7, 38.2, 36.3, 35.8, 35.2, 31.7, 29.9, 26.3, 24.4, 22.7, 14.2; IR (Neat Film, NaCl) 3028, 2930, 2858, 1727, 1683, 1442, 1350, 1273, 1170, 699 cm-1; HRMS (ESI) m/z calc’d for C31H45N2O5 [M+NH4]+: 525.3323, found 525.3329; [α]25 +0.25 (c 1.8, CHCl3, 76% ee). 
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6o) 
Representative Procedure I.  Compound 6o was prepared using General Procedure H with 5o (15.2 mg, 60 mol) to afford a clear oil (14.6 mg, 78% yield): 1H NMR (500 MHz, CDCl3) δ 6.84 (dt, J = 15.4, 7.7 Hz, 1H), 5.88 (dt, J = 15.5, 1.5 Hz, 1H), 4.48 – 4.31 (m, 2H), 4.05 (dd, J = 8.5, 7.6 Hz, 2H), 3.72 (s, 3H), 2.83 – 2.63 (m, 2H), 2.14 – 1.95 (m, 2H), 1.82 – 1.67 (m, 2H), 1.28 (h, J = 7.1 Hz, 2H), 1.22 – 1.12 (m, 1H), 1.06 (ttd, J = 12.3, 7.3, 4.5 Hz, 1H), 0.87 (t, J = 7.3 Hz, 3H), 0.79 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 176.6, 166.8, 152.4, 145.5, 123.8, 62.4, 52.9, 51.6, 45.6, 35.6, 32.2, 26.7, 25.5, 23.2 14.1, 8.8; IR (Neat Film, NaCl) 2959, 2875, 1778, 1722, 1682, 1470, 1436, 1385, 1257, 1195, 1175, 1109, 1045 cm-1; HRMS (FAB+) m/z calc’d for C16H26NO5 [M+H]+: 312.1811, found 312.1791; [α]25 +0.50 (c 1.3, CHCl3, 69% ee). 
  
S37  
 
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)undec-2-enoate (6p) 
Representative Procedure I.  Compound 6p was prepared using General Procedure H with 5p (16.5 mg, 59 mol) to afford a clear oil (16.3 mg, 82% yield): 1H NMR (500 MHz, CDCl3) δ 6.91 – 6.74 (m, 1H), 5.87 (dt, J = 15.5, 1.5 Hz, 1H), 4.39 (t, J = 8.0 Hz, 2H), 4.05 (t, J = 8.0 Hz, 2H), 3.71 (s, 3H), 2.86 – 2.62 (m, 2H), 2.14 – 1.91 (m, 2H), 1.84 – 1.66 (m, 2H), 1.31 – 1.12 (m, 7H), 1.12 – 1.00 (m, 1H), 0.86 (t, J = 6.8 Hz, 3H), 0.79 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 176.6, 166.8, 152.4, 145.6, 123.7, 62.4, 52.9, 51.6, 45.6, 35.6, 32.4, 31.7, 29.7, 25.6, 24.4, 22.7, 14.2, 8.8; IR (Neat Film, NaCl) 2956, 2929, 2858, 1779, 1723, 1682, 1469, 1385, 1254, 1194, 1110, 1046 cm-1; HRMS (FAB+) m/z calc’d for C18H30NO5 [M+H]+: 340.2124, found 340.2116; [α]25 +2.41 (c 1.5, CHCl3, 73% ee). 
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3.4 Evidence of Absolute Stereochemistry 
 
 
 
 
(S)-N-Benzyl-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enamide (S11) 
To an oven-dried round-bottom flask and magnetic stir bar was added 5j (60 mg, 0.143 mmol) followed by anhydrous THF (1.4 mL).  The solution was stirred under nitrogen at room temperature.  A solution of NaOH in anhydrous methanol (0.17 mL, 1.0 M) was added dropwise by syringe.  The reaction was stirred at room temperature for 45 min.  Afterward, the reaction mixture was diluted with ethyl acetate and quenched with water.  The mixture was partitioned between water and ethyl acetate and the aqueous layer was extracted two additional times with ethyl acetate.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (10/90 to 12/88 EtOAc/hexanes) to provide the product as an amorphous white solid (30.2 mg, 58% yield); 1H NMR (500 MHz, CDCl3) δ 7.36 – 7.24 (m, 5H), 6.37 (s, 1H), 5.80 – 5.69 (m, 1H), 5.08 – 5.06 (m, 1H), 5.06 – 5.03 (m, 1H), 4.49 – 4.38 (m, 2H), 3.68 (td, J = 6.7, 1.5 Hz, 2H), 2.40 (ddt, J = 13.7, 7.1, 1.2 Hz, 1H), 2.27 (ddt, J = 13.7, 7.7, 1.1 Hz, 1H), 1.93 (dt, J = 13.7, 6.7 Hz, 1H), 1.69 (dt, J = 14.1, 6.7 Hz, 1H), 1.20 (s, 3H), 0.86 (s, 9H), 0.02 – -0.00 (m, 6H); 
13C NMR (126 MHz, CDCl3) δ 176.4, 138.8, 134.3, 128.8, 127.9, 127.5, 118.3, 60.1, 44.7, 44.7, 43.7, 41.4, 26.1, 22.3, 18.4, -5.3, -5.3; IR (Neat Film, NaCl) 3343, 2955, 2929, 2856, 1640, 1531, 1254, 1095, 836 cm-1; HRMS (FAB+) m/z calc’d for C21H36NO2Si [M+H]+: 362.2514, found 362.2515; [α]25 –2.93 (c 2.5, CHCl3, 94% ee). 
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(S)-N-Benzyl-2-(2-hydroxyethyl)-2-methylpent-4-enamide (S12) 
To an oven-dried 2-dram vial and magnetic stir bar was added S11 (30 mg, 0.083 mmol) followed by anhydrous THF (0.5 mL).  The solution was stirred under nitrogen at room temperature.  A solution of TBAF in anhydrous THF (0.17 mL, 1.0 M) was added dropwise by syringe.  The reaction was stirred at room temperature for 2 h.  Afterward, the reaction mixture was quenched with saturated ammonium chloride.  The mixture was partitioned between water and dichloromethane and the aqueous layer was extracted two additional times with dichloromethane.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (60/40 EtOAc/hexanes) to provide the product as an oil (19.5 mg, 58% yield): 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.24 (m, 5H), 6.10 (s, 1H), 5.78 – 5.69 (m, 1H), 5.11 – 5.09 (m, 1H), 5.09 – 5.05 (m, 1H), 4.45 (d, J = 5.5 Hz, 2H), 3.78 (dt, J = 11.8, 6.1 Hz, 1H), 3.74 – 3.65 (m, 1H), 2.56 (s, 1H), 2.48 (ddt, J = 13.7, 7.0, 1.3 Hz, 1H), 2.22 (ddt, J = 13.7, 7.7, 1.2 Hz, 1H), 2.00 (ddd, J = 14.4, 7.3, 5.5 Hz, 1H), 1.70 (ddd, J = 14.4, 6.6, 5.4 Hz, 1H), 1.22 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 177.5, 138.3, 133.7, 128.9, 127.9, 127.7, 118.9, 59.3, 44.5, 44.4, 44.0, 41.5, 22.2; IR (Neat Film, NaCl) 3335, 2927, 1634, 1538, 1249 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C15H21NO2 [M+H]+: 248.1645, found 248.1651; [α]25 –61.06 (c 1.63, CHCl3, 94% ee). 
 
(S)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((S)-8) 
To an oven-dried 2-dram vial and magnetic stir bar was added S12 (19.5 mg, 0.079 mmol) followed by anhydrous 
THF (0.20 mL).  The solution was stirred under nitrogen at 0 °C.  Triethylamine (12 L, 0.087 mmol) was added dropwise by syringe followed by a solution of methanesulfonyl chloride in THF (0.10 mL, 0.79 M).  The reaction was stirred at 0 °C for 0.5 h.  A separate oven-dried 2-dram vial and magnetic stir bar was charged with NaHMDS (46 mg, 0.253 mmol) and THF (0.25 mL).  The reaction mixture was cannulated into the NaHMDS solution at 0 °C over 5 minutes.  This solution was warmed to room temperature and stirred overnight.  Afterward, the reaction mixture was quenched with saturated ammonium chloride.  The mixture was partitioned between water and ethyl acetate and the aqueous layer was extracted two additional times with ethyl acetate.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by preparative TLC (40/60 EtOAc/hexanes) to provide the product as an oil (8.4 mg, 46% yield); 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (m, 5H), 5.82 –5.74 (m, 1H), 5.18 – 5.06 (m, 2H), 4.53 – 4.42 (m, 2H), 3.20 – 3.10 (m, 2H), 2.37 (ddt, J = 13.7, 6.7, 1.3 Hz, 1H), 2.25 (ddt, J = 13.8, 8.2, 1.1 Hz, 1H), 2.03 (ddd, J = 12.8, 8.2, 6.4 Hz, 1H), 1.73 (ddd, J = 12.9, 8.0, 5.5 Hz, 1H), 1.20 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 178.6, 136.7, 134.1, 128.7, 128.1, 127.6, 118.4, 46.8, 44.1, 43.4, 42.3, 30.4, 23.2; IR (Neat Film, NaCl) 3002, 2962, 1686, 1454, 1431, 1291, 917, 701 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C15H20NO [M+H]+: 230.1539, found 230.1549; [α]25 26.10 (c 0.70, CHCl3, 94% ee). 
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(R)-3-Allyl-3-methylpyrrolidin-2-one (S13) 
To a round-bottom flask and magnetic stir bar was added 7[17] (98% ee) (80 mg, 0.33 mmol) followed by MeOH (4.0 mL).  The solution was stirred under nitrogen at 0 °C.  A solution of NaOH (0.61 mL, 2.0 M, 1.2 mmol) was added dropwise by syringe.  The reaction was stirred at 0 °C for 1.5 h.  The mixture was partitioned between brine and diethyl ether.  The organic layer was washed with saturated sodium bicarbonate solution followed by brine, dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by flash chromatography (80/20 to 100/0 EtOAc/hexanes) to provide the product as an amorphous white solid (28.3 mg, 62% yield); 1H NMR (500 MHz, CDCl3) δ 6.49 (s, 1H), 5.84 – 5.70 (m, 1H), 5.13 – 5.09 (m, 1H), 5.08 (p, J = 1.2 Hz, 1H), 3.34 – 3.19 (m, 2H), 2.33 – 2.25 (m, 1H), 2.19 (ddt, J = 13.6, 8.2, 1.1 Hz, 1H), 2.15 – 2.06 (m, 1H), 1.86 – 1.76 (m, 1H), 1.15 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 182.9, 134.1, 118.4, 43.1, 42.0, 39.0, 33.0, 22.8; IR (Neat Film, NaCl) 3233, 3077, 2928, 1697, 1295, 915 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C8H14NO [M+H]+: 140.1070, found 140.1071; [α]25 –33.10 (c 2.27, CHCl3, 98% ee). 
 
(R)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((R)-8): 
To an oven-dried 2-dram vial and magnetic stir bar was added S13 (28.3 mg, 0.203 mmol) followed by anhydrous DMF (1.0 mL).  The solution was stirred under nitrogen at 0 °C.  Sodium hydride (8.1 mg, 0.203 mmol) was added portion-wise over two minutes.  The reaction was stirred at 0 °C for 40 min.  To this solution was added benzyl 
bromide (30 L, 0.256 mmol) dropwise through by syringe.  This solution was warmed to room temperature and stirred for 2 h.  Afterward, the reaction mixture was quenched with saturated ammonium chloride.  The mixture was partitioned between water and ethyl acetate and the aqueous layer was extracted two additional times with ethyl acetate.  The combined organic layers were washed with brine (50 mL), dried with sodium sulfate and filtered.  This mixture was concentrated in vacuo and purified by preparative TLC (40/60 EtOAc/hexanes) to provide the product as an oil (27 mg, 59% yield).  Characterization data matched previously synthesized material;[17] [α]25 –33.10 (c 2.27, CHCl3, 98% ee). 
 
4 References 
[1] Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, 62, 7512–7515. http://dx.doi.org/10.1021/jo971176v  [2] Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518–1520. http://dx.doi.org/10.1021/om9503712  [3] Krout, M. R.; Mohr, J. T.; Stoltz, B. M. Org. Synth. 2009, 86, 181–193. http://dx.doi.org/10.15227/orgsyn.086.0181  [4] McDougal, N. T.; Streuff, J.; Mukherjee, H.; Virgil, S. C.; Stoltz, B. M. Tetrahedron Lett. 2010, 51, 5550–5554. http://dx.doi.org/10.1016/j.tetlet.2010.08.039  [5] Zhang, X.; Zhang, Y.; Huang, J.; Hsung, R. P.; Kurtz, K. C. M.; Oppenheimer, J.; Petersen, M. E.; Sagamanova, I. K.; Shen, L.;Tracey, M. R. J. Org. Chem. 2006, 71, 4170–4177. http://doi.org/dx/10.1021/jo060230h  
S42  
 [6] Frederick, M. O.; Mulder, J. A.; Tracey, M. R.; Hsung, R. P.; Huang, J.; Kurtz, K. C. M.; Shen, L.; Douglas, C. J. J. Am. Chem. Soc. 2003, 125, 2368–2369. http://dx.doi.org/10.1021/ja021304j  [7] Hamada, T.; Ye, X.; Stahl, S. S. J. Am. Chem. Soc. 2008, 130, 833–835. http://dx.doi.org/10.1021/ja077406x  [8] Zhang, Y.; Hsung, R. P.; Tracey, M. R.; Kurtz, K. M. C.; Vera, E. L. Org. Lett. 2004, 6, 1151–1154. http://dx.doi.org/10.1021/ol049827e  [9] Saito, N.; Katayama, T.; Sato, Y. Org. Lett. 2008, 10, 3829–3832. http://dx.doi.org/10.1021/ol801534e  [10] Jouvin, K.; Heimburger, J.; Evano, G. Chem. Sci. 2012, 3, 756–760. http://dx.doi.org/10.1039/c2sc00842d  [11] Jouvin, K.; Couty, F.; Evano, G. Org. Lett. 2010, 12, 3272–3275. http://dx.doi.org/10.1021/ol101322k  [12] White, D. E.; Stewart, E. C.; Seashore-Ludlow, B. A.; Grubbs, R: H.; Stoltz, B. M. Tetrahedron 2010, 66, 4668–4686. http://dx.doi.org/10.1016/j.tet.2010.04.128  [13] Vishnumurthy, K.; Makriyannis, A. J. Comb. Chem. 2010, 12, 664–669. http://dx.doi.org/doi/abs/10.1021/cc100068a  [14] Stankevič, M.; Włodarczyk, A. Tetrahedron 2013, 69, 73–81. http://dx.doi.org/10.1016/j.tet.2012.10.064  [15] Fox, M. E.; Gerlach, A.; Lennon, I. C.; Meek, G.; Praquin, C. Synthesis 2005, 19, 3196–3198. http://dx.doi.org/10.1055/s-2005-918444  [16] Trost, B. M.; Michaelis, D. J.; Charpentier, J.; Xu, J. Angew. Chem. Int. Ed. 2012, 51, 204–208.  http://dx.doi.org/10.1002/anie.201105801  [17] Behenna, D. C.; Liu, Y.; Yurino, T.; Kim, J.; White, D. E.; Virgil, S. C.; Stoltz, B. M. Nature Chem. 2012, 4, 130–133. http://dx.doi.org/10.1038/nchem.1222  [18] McDougal, N. T.; Virgil, S. C.; Stoltz, B. M. Synlett 2010, 11, 1712–1716. http://dx.doi.org/10.1055/s-0030-1258094   
S43  
 
5 Spectra 
3-(Hex-1-yn-1-yl)oxazolidin-2-one  (1a)   
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3-(Oct-1-yn-1-yl)oxazolidin-2-one  (1q)   
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Methyl benzyl(hex-1-yn-1-yl)carbamate  (1d)   
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Ethyl benzyl(hex-1-yn-1-yl)carbamate  (1e)   
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tert-Butyl benzyl(hex-1-yn-1-yl)carbamate  (1f)   
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S48  
 
Benzyl benzyl(hex-1-yn-1-yl)carbamate  (1g)   
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S49  
 
Methyl (4-chlorophenyl)(hex-1-yn-1-yl)carbamate  (1h)   
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Methyl benzyl(oct-1-yn-1-yl)carbamate  (1i)   
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155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 ppm
14
.1
3
18
.5
1
22
.6
6
28
.5
0
28
.9
8
31
.4
2
54
.0
1
70
.6
6
73
.8
8
12
7.
93
12
8.
45
12
8.
52
13
6.
38
15
6.
29
400-166-20150921-CDCl3-p506
S51  
 
Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)carbamate  (1j)  
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S52  
 
Methyl benzyl(phenylethynyl)carbamate  (1k)   
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S53  
 
3-(Prop-1-yn-1-yl)oxazolidin-2-one  (1b) 
 
S54  
 
3-(Hex-1-yn-1-yl)benzo[d]oxazol-2(3H)-one  (1c)   
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S55  
 
(E)-Methyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4d) 
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S56  
 
(E)-Ethyl benzyl(1-iodo-2-methylhex-1-enyl)carbamate (4e) 
 
 
S57  
 
(E)-tert-butyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4f) 
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S58  
 
(E)-Benzyl benzyl(1-iodo-2-methylhex-1-en-1-yl)carbamate (4g) 
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S59  
 
(E)-Methyl (4-chlorophenyl)(1-iodo-2-methylhex-1-en-1-yl)carbamate (4h)
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S60  
 
(E)-Methyl benzyl(1-iodo-2-methyloct-1-enyl)carbamate (4i)
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S61  
 
(E)-Methyl benzyl(4-((tert-butyldimethylsilyl)oxy)-1-iodo-2-methylbut-1-en-1-yl)carbamate (4j) 
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S62  
 
(E)-Methyl benzyl(1-iodo-2-phenylprop-1-en-1-yl)carbamate (4k) 
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S63  
 
(E)-Methyl benzyl(2-ethyl-1-iodohex-1-en-1-yl)carbamate (4l) 
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(E)-Methyl benzyl(2-ethyl-1-iodooct-1-en-1-yl)carbamate (4m) 
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(E)-Methyl benzyl(1-iodo-2-propyloct-1-en-1-yl)carbamate (4n)  
 
 
S66  
 
(Z)-Methyl benzyl(1-iodo-2-(3-phenylpropyl)hex-1-en-1-yl)carbamate (4o)  
 
 
S67  
 
(E)-3-(2-Ethyl-1-iodohex-1-en-1-yl)oxazolidin-2-one (4p)  
 
 
  
S68  
 
(E)-3-(2-Ethyl-1-iodooct-1-en-1-yl)oxazolidin-2-one  (4q)  
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(E)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3a)  
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(Z)-Allyl (2-methyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3b)  
 
 
  
S71  
 
(E)-Allyl (2-methyl-1-(2-oxobenzo[d]oxazol-3(2H)-yl)hex-1-en-1-yl) carbonate (3c)  
 
 
S72  
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3d)  
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(E)-Ethyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3e)  
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(E)-tert-Butyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3f)  
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(E)-Benzyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(benzyl)carbamate (3g)  
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(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methylhex-1-en-1-yl)(4-chlorophenyl)carbamate (3h) 
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(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-methyloct-1-en-1-yl)(benzyl)carbamate (3i) 
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S78  
 
(E)-Methyl benzyl(2,2,3,3,7-pentamethyl-10-oxo-4,9,11-trioxa-3-silatetradeca-7,13-dien-8-yl)carbamate (3j) 
 
  
S79  
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-phenylprop-1-en-1-yl)(benzyl)carbamate (3k) 
 
 
  
S80  
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-ethylhex-1-en-1-yl)(benzyl)carbamate (3l)  
 
S81  
 
(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-ethyloct-1-en-1-yl)(benzyl)carbamate (3m)  
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(E)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-propyloct-1-en-1-yl)(benzyl)carbamate (3n)  
 
S83  
 
(Z)-Methyl (1-(((allyloxy)carbonyl)oxy)-2-(3-phenylpropyl)oct-1-en-1-yl)(benzyl)carbamate (3o) 
 
  
S84  
 
(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)hex-1-en-1-yl) carbonate (3p)  
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(E)-Allyl (2-ethyl-1-(2-oxooxazolidin-3-yl)oct-1-en-1-yl) carbonate (3q) 
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Methyl 2-bromo-5-(trifluoromethyl)benzoate (S2) 
  
 1 H 
NM
R (3
00 M
Hz, 
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l 3) o
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d S2
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Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphoryl)-5-(trifluoromethyl)benzoate (S3) 
       
 1 H 
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R (5
00 M
Hz, 
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l 3) o
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 13C NMR (126 MHz, CDCl3) of compound S3. 
Infrared spectrum (Thin Film, NaCl) of compound S3. 
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 19F NMR (282 MHz, CDCl3) of compound S3. 
 31P NMR (121 MHz, CDCl3) of compound S3. 
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Methyl 2-(bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoate (S4) 
       
 1 H 
NM
R (5
00 M
Hz, 
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l 3) o
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d S4
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  13C NMR (126 MHz, CDCl3) of compound S4. 
Infrared spectrum (Thin Film, NaCl) of compound S4. 
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 19F NMR (282 MHz, CDCl3) of compound S4. 
 31P NMR (121 MHz, CDCl3) of compound S4. 
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2-(Bis(4-(trifluoromethyl)phenyl)phosphanyl)-5-(trifluoromethyl)benzoic acid (S5) 
        
 1 H 
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  13C NMR (126 MHz, CDCl3) of compound S5. 
Infrared spectrum (Thin Film, NaCl) of compound S5. 
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 19F NMR (282 MHz, CDCl3) of compound S5. 
 31P NMR (121 MHz, CDCl3) of compound S5. 
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Electron deficient C2-symmetric ligand (L7)        
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 13C NMR (126 MHz, CDCl3) of compound L7. 
Infrared spectrum (Thin Film, NaCl) of compound L7. 
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 19F NMR (282 MHz, CDCl3) of compound L7. 
 31P NMR (121 MHz, CDCl3) of compound L7. 
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Methyl 2-(di-o-tolylphosphanyl)benzoate (S9)       
 1 H 
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R (5
00 M
Hz, 
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l 3) o
f co
mp
oun
d S9
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  13C NMR (126 MHz, CDCl3) of compound S9. 
Infrared spectrum (Thin Film, NaCl) of compound S9. 
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 31P NMR (121 MHz, CDCl3) of compound S9. 
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Sterically hindered C2-symmetric ligand (L8)        
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 13C NMR (126 MHz, CDCl3) of compound L8. 
Infrared spectrum (Thin Film, NaCl) of compound L8. 
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 31P NMR (121 MHz, CDCl3) of compound L8. 
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3-(2-Allyl-2-methylhexanoyl)oxazolidin-2-one (5ab)     
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5a
b. 
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 13C NMR (126 MHz, CDCl3) of compound 5ab. 
Infrared spectrum (Thin Film, NaCl) of compound 5ab. 
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Methyl (E)-5-methyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6ab)     
 1 H 
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R (5
00 M
Hz, 
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l 3) o
f co
mp
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d 6a
b. 
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 13C NMR (126 MHz, CDCl3) of compound 6ab. 
Infrared spectrum (Thin Film, NaCl) of compound 6ab. 
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1-(2-Allyl-2-methylhexanoyl)indolin-2-one (5c)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5c
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 13C NMR (126 MHz, CDCl3) of compound 5c. 
Infrared spectrum (Thin Film, NaCl) of compound 5c. 
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Methyl (E)-5-methyl-5-(2-oxo-2,3-dihydrobenzo[d]oxazole-3-carbonyl)non-2-enoate (6c)  
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6c
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 13C NMR (126 MHz, CDCl3) of compound 6c. 
Infrared spectrum (Thin Film, NaCl) of compound 6c. 
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Methyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5d)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5d
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   13C NMR (126 MHz, CDCl3) of compound 5d. 
Infrared spectrum (Thin Film, NaCl) of compound 5d. 
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 Ethyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5e)   
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5e
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 13C NMR (126 MHz, CDCl3) of compound 5e. 
Infrared spectrum (Thin Film, NaCl) of compound 5e 
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tert-Butyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5f)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5f
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 13C NMR (126 MHz, CDCl3) of compound 5f. 
Infrared spectrum (Thin Film, NaCl) of compound 5f. 
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Benzyl (R)-(2-allyl-2-methylhexanoyl)(benzyl)carbamate (5g)   
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5g
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 13C NMR (126 MHz, CDCl3) of compound 5g. 
Infrared spectrum (Thin Film, NaCl) of compound 5g. 
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Methyl (R)-(2-allyl-2-methylhexanoyl)(4-chlorophenyl)carbamate (5h)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5h
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 13C NMR (126 MHz, CDCl3) of compound 5h. 
Infrared spectrum (Thin Film, NaCl) of compound 5h. 
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Methyl (R)-(2-allyl-2-methyloctanoyl)(benzyl)carbamate (5i)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5i
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 13C NMR (126 MHz, CDCl3) of compound 5i. 
Infrared spectrum (Thin Film, NaCl) of compound 5i. 
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Methyl (S)-benzyl(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enoyl)carbamate (5j)   
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5j
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 13C NMR (126 MHz, CDCl3) of compound 5j. 
Infrared spectrum (Thin Film, NaCl) of compound 5j. 
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Methyl (S)-benzyl(2-methyl-2-phenylpent-4-enoyl)carbamate (5k)  
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5k
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 13C NMR (126 MHz, CDCl3) of compound 5k. 
Infrared spectrum (Thin Film, NaCl) of compound 5k. 
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Methyl (R)-(2-allyl-2-ethylhexanoyl)(benzyl)carbamate (5l)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5l
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 13C NMR (126 MHz, CDCl3) of compound 5l. 
Infrared spectrum (Thin Film, NaCl) of compound 5l. 
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Methyl (R)-(2-allyl-2-ethyloctanoyl)(benzyl)carbamate (5m)   
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5m
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 13C NMR (126 MHz, CDCl3) of compound 5m. 
Infrared spectrum (Thin Film, NaCl) of compound 5m. 
S133  
 
Methyl (S)-(2-allyl-2-(3-phenylpropyl)octanoyl)(benzyl)carbamate (5n)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5n
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 13C NMR (126 MHz, CDCl3) of compound 5n. 
Infrared spectrum (Thin Film, NaCl) of compound 5n. 
S135  
 
(R)-3-(2-Allyl-2-ethylhexanoyl)oxazolidin-2-one (5o)   
 
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5o
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 13C NMR (126 MHz, CDCl3) of compound 5o. 
Infrared spectrum (Thin Film, NaCl) of compound 5o. 
S137  
 
(R)-3-(2-Allyl-2-ethyloctanoyl)oxazolidin-2-one (5p)     
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 5p
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 13C NMR (126 MHz, CDCl3) of compound 5p. 
Infrared spectrum (Thin Film, NaCl) of compound 5p. 
S139  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6d)      
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6d
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 13C NMR (126 MHz, CDCl3) of compound 6d. 
Infrared spectrum (Thin Film, NaCl) of compound 6d. 
S141  
 
Methyl (R,E)-5-(benzyl(ethoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6e)      
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6e
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 13C NMR (126 MHz, CDCl3) of compound 6e. 
Infrared spectrum (Thin Film, NaCl) of compound 6e 
S143  
 
Methyl (R,E)-5-(benzyl(tert-butoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6f)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6f
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 13C NMR (126 MHz, CDCl3) of compound 6f. 
Infrared spectrum (Thin Film, NaCl) of compound 6f. 
S145  
 
Methyl (R,E)-5-(benzyl((benzyloxy)carbonyl)carbamoyl)-5-methylnon-2-enoate (6g)     
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6g
. 
 
 
S146  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 13C NMR (126 MHz, CDCl3) of compound 6g. 
Infrared spectrum (Thin Film, NaCl) of compound 6g. 
S147  
 
Methyl (R,E)-5-((4-chlorophenyl)(methoxycarbonyl)carbamoyl)-5-methylnon-2-enoate (6h)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6h
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 13C NMR (126 MHz, CDCl3) of compound 6h. 
Infrared spectrum (Thin Film, NaCl) of compound 6h. 
S149  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-methylundec-2-enoate (6i)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6i
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 13C NMR (126 MHz, CDCl3) of compound 6i. 
Infrared spectrum (Thin Film, NaCl) of compound 6i. 
S151  
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-7-((tert-butyldimethylsilyl)oxy)-5-methylhept-2-enoate (6j)   
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
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 13C NMR (126 MHz, CDCl3) of compound 6j. 
Infrared spectrum (Thin Film, NaCl) of compound 6j. 
S153  
 
Methyl (S,E)-6-(benzyl(methoxycarbonyl)amino)-5-methyl-6-oxo-5-phenylhex-2-enoate (6k)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6k
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 13C NMR (126 MHz, CDCl3) of compound 6k. 
Infrared spectrum (Thin Film, NaCl) of compound 6k. 
S155  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylnon-2-enoate (6l)       
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6l
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 13C NMR (126 MHz, CDCl3) of compound 6l. 
Infrared spectrum (Thin Film, NaCl) of compound 6l. 
S157  
 
Methyl (R,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-ethylundec-2-enoate (6m)     
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6m
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 13C NMR (126 MHz, CDCl3) of compound 6m. 
Infrared spectrum (Thin Film, NaCl) of compound 6m. 
S159  
 
Methyl (S,E)-5-(benzyl(methoxycarbonyl)carbamoyl)-5-(3-phenylpropyl)undec-2-enoate (6n)      
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6n
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 13C NMR (126 MHz, CDCl3) of compound 6n. 
Infrared spectrum (Thin Film, NaCl) of compound 6n. 
S161  
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)non-2-enoate (6o)    
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6o
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 13C NMR (126 MHz, CDCl3) of compound 6o. 
Infrared spectrum (Thin Film, NaCl) of compound 6o. 
S163  
 
Methyl (R,E)-5-ethyl-5-(2-oxooxazolidine-3-carbonyl)undec-2-enoate (6p)      
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 6p
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 13C NMR (126 MHz, CDCl3) of compound 6p. 
Infrared spectrum (Thin Film, NaCl) of compound 6p 
S165  
 
(S)-N-Benzyl-2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-methylpent-4-enamide (S11)  
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
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oun
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 13C NMR (126 MHz, CDCl3) of compound S11. 
Infrared spectrum (Thin Film, NaCl) of compound S11. 
S167  
 
(S)-N-Benzyl-2-(2-hydroxyethyl)-2-methylpent-4-enamide (S12)        
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
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oun
d S1
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 13C NMR (126 MHz, CDCl3) of compound S12. 
Infrared spectrum (Thin Film, NaCl) of compound S12. 
S169  
 
(S)-3-Allyl-1-benzyl-3-methylpyrrolidin-2-one ((S)-8)        
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
mp
oun
d 8.
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 13C NMR (126 MHz, CDCl3) of compound 8. 
Infrared spectrum (Thin Film, NaCl) of compound 8. 
S171  
 
(R)-3-Allyl-3-methylpyrrolidin-2-one (S13)        
 1 H 
NM
R (5
00 M
Hz, 
CDC
l 3) o
f co
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d S1
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 13C NMR (126 MHz, CDCl3) of compound S13. 
Infrared spectrum (Thin Film, NaCl) of compound S13. 
